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Proteins as well as nucleic acids play a crucial role in many cellular processes. Hence, chemists in 
collaboration with biologists and physicists are involved in the development of new methods to study 
these biomolecules in their native environment.[1] To investigate their locations, structures and distinct 
processes they are involved in, fast, sensitive and reliable detection methods are needed.[2] 
Additionally, reporter groups need to be attached to the protein of interest (POI), e. g. by radioactive 
labelling or the introduction of isotope markers, in order to track these molecules.[3] One of the most 
common methods is the labelling with fluorophores. It has several advantages over other labelling 
techniques such as its non-destructive nature and high sensitivity, which allows even single molecule 
detection.[4] Furthermore, fluorophores are available in multiple colours enabling the simultaneous 
detection of different processes and proteins.  
 
Modern fluorescent probes that are introduced to the POIs range from small organic fluorophores, 
which are widely applied for chemical labelling, to fluorescent proteins of larger size. Since the first 
fluorescent labelling of proteins in vivo with the green fluorescent protein (GFP) in 1994, an increasing 
number of fluorescent proteins have been developed, such as the cyan fluorescent protein or the 
yellow fluorescent protein as well as new fluorescent proteins derived from other bioluminescent 
species.[5,6] These fluorescent proteins are attached to POIs on DNA level and introduced into the 
required system by recombinant expression. Although, this method of fluorescent labelling is widely 
applied, limitations are the size of the fluorescent protein (GFP contains 238 amino acids) and thereby 
its influence on function, movement and activity of POIs.[6] Due to these disadvantages of fluorescent 
proteins, a number of small synthetic fluorescent probes have been investigated for in vivo labelling. 
Synthetic fluorescent probes are variable in properties and functionalities and can be derivatised with 
a number of reactive groups in order to link them to POIs. Even though labelling with synthetic 
fluorescent probes in vivo might be difficult, as reactivity and specificity towards POIs must be high to 
avoid background labelling, the introduction of bioorthogonal groups into POIs by recombinant 
expression is one way to realize it. Furthermore, synthetic fluorescent probes are combined with 
proteins that target membrane proteins on the cell surface. This chemical labelling prior to the 




fluorescent marker. The POIs may even be synthetically modified by the introduction of additional 
functionalities. 
 
Ion channels are a class of membrane proteins, which are widely investigated and represent interesting 
targets for labelling studies. They are pore forming proteins, which allow the inward and outward flux 
of ions across the cell membrane and consequently distribute to electrical potential generation and 
action potential propagation.[7] The ion channel distribution and localisation along cell membranes are 
of high interest for researches to clarify the picture of how they establish their mode of action during 
stimulus conduction. In order to label ion channels, specific binding tools need to be acquired, which 
bind selectively and are easily modified in order to attach a fluorescent probe. Nowadays, a number 
of specific binding neurotoxins, derived from animal venoms, have been identified which interact with 
specific ion channels or even ion channel subtypes. 
 
In this thesis a number of novel labelled neurotoxins (conotoxin, pompilidotoxin and iberiotoxin) for 
the selective binding to specific ion channels will be presented. Following an in-depth structural 
analysis of functional residues important for the ion channel/neurotoxin interaction, an adjusted 
synthetic strategy is developed to prevent reduced binding affinities. For one of the synthesized 
neurotoxins (conotoxin), bearing three disulphide bridges, an elaborate synthetic pathway is 
developed to induce the correct disulphide linkages and therefore, enforce the structure necessary for 
binding to the specific ion channel. The selective introduction of a fluorescent marker will be 
accomplished by bioorthogonal strategies making use of synthetically inserted alkyne or thiol 
functionalities or natural occurring amines. These novel synthesized labelled neurotoxins, which retain 
their activity, allow the investigation of ion channels regarding their quantification, distribution and 
localisation by our cooperation partners ANDREAS NEEF and co-workers, and the SCHILD research group 
(see Scheme 1). Furthermore, a photocleavable protecting group is introduced into a conotoxin on 
functional residues, which are important for binding. Thereby, a neurotoxin will be available, which 
can be switched from the inactive state (no binding affinity) to the active state (binding and thereby 





Scheme 1: Overview of the synthetic approach for labelling neurotoxins. The first step is the synthesis of a 
linear peptide containing either alkyne, thiol or amine functionality for bioorthogonal labelling. For 
neurotoxins containing disulphide bridges, multiple synthetic steps are necessary to consecutively form the 
complex structure. Subsequently, the labelling reaction is performed without affecting the binding side of the 
neurotoxin, thereby, enabling investigations on specific ion channels. 
     
In a second project in cooperation with MARCO TARANTOLA and co-workers, the labelling of a nucleotide 
will be described. Cyclic adenosine-3’,5’-monophosphate (cAMP) acts as a chemoattractant for the 
amoeboid Dictyostelium discoideum, which migrates in a cAMP gradient towards the highest 
concentration. With the intention of labelling cAMP, an alkyne moiety will be introduced in two 
different positions. By the introduction of a bioorthogonal group, such as an alkyne, a number of 
different groups and functional tools can be linked to cAMP via copper-catalysed azide-alkyne 
cycloaddition of functionalised azides e. g. different fluorescent probes. In this thesis two azide 
functionalised fluorophores (either Alexa Fluor® 555 or 488) will be attached and these labelled cAMP 
derivatives may help to elucidate the cAMP dependent chemotaxis of the amoeboid Dictyostelium 
discoideum. This offers a tool for the quantification and visualisation of cAMP concentrations 
(monitored by a confocal laser scanning microscope), which are necessary for an induction of 










2 Fluorescent labelling 
 
 
Fluorescent labelling is generally performed by linking a reactive derivative of the fluorophore to a 
protein of interest (POI) containing the corresponding reactive functionality. Combination of 
fluorescent labelling methods with advanced fluorescence microscopy allows to investigate in vivo/in 
vitro protein distribution, translocation and interaction. The different methods, by which labelling is 
mostly accomplished, are further described in section 2.1. Certain requirements must be considered 
before selecting one of the methods provided. On the one hand, the size of the fluorescent probe and 
its stability towards different environments need to be reflected in order to avoid changes in the mode 
of action and to maintain the activity of the POI. On the other hand, the efficiency and applicability of 
the labelling reaction to the POI, with a preference for covalent linkage, needs to be considered.[3]  
2.1 Fluorescent labelling techniques 
Fluorescent labelling methods can be divided into four main strategies: genetic, enzymatic, tag or 
chemical labelling, as described in a review by SAHOO (see Figure 1).[3] One of the most applied tools 
for genetic labelling, which is used in vivo, is the recombinant expression of POI together with 
fluorescent proteins. Due to the large size of fluorescent proteins of approximately 27 kDa, proteins 
such as GFP easily influence the structure and activity of POIs.[8] Additionally, unnatural fluorescent 
amino acids are incorporated into proteins via tRNA that has previously been aminoacylated with an 
unnatural amino acid, such as 7-methoxycoumarine modified aspartic acid.[9] For the introduction of 
commercially available fluorophores, unnatural amino acids with non-proteinogenic reactive groups 
like azide, alkyne or ketone may be introduced into POIs, which are derivatised with the respective 
fluorophores. Due to the low yields of this labelling technique, this method is seldom utilised. The 
direct labelling of tRNA for the study of its dynamics on ribosome during translation is accomplished 
via selective reduction of dihydrouridine followed by an attachment of dihydrazide modified 
fluorophore (see Figure 1: genetic).[10] These genetic labelling methods are frequently used for in vivo 
labelling. Nowadays, enzymatic labelling attracts even more attention for both in vivo and in vitro 
labelling. Enzymatic reactions are generally fast, efficient and selective, though the limitations are, that 




application of Sortase A, the most commonly used enzyme for labelling reactions, two motifs are linked 
to the POI and fluorophore, respectively: on the one hand, a Leu-Pro-X-Thr-Gly (LPXTG) motif at the 
C-terminus of the POI or fluorophore and on the other hand, a polyglycine sequence at the N-terminus 
of either.[11] Sortase A recognises the LPXTG motif, cleaves the Thr-Gly peptide bond and forms a bond 
to the N-terminus of the polyglycine sequence. Sortase A has been widely used and allows even 
unnatural moieties beyond the LPXTG or polyglycine motif.[12] The disadvantage is its characteristic to 
hydrolyse intrinsic peptide bonds, whenever the LPXTG motif is present.  
 
 
Figure 1: Overview of the various approaches for labelling proteins (figure adapted from the review by 
SAHOO).[3] Genetic labelling is achieved by the introduction of a fluorescent protein (e. g. GFP) or unnatural 
fluorescent amino acids or a modification of tRNA. Chemical labelling is conducted by the application of 
unnatural amino acids, for reactions via copper(I)-catalysed azide-alkyne cycloaddition and inverse-demand 
DIELS-ALDER reactions, or natural amino acids via activated ester or maleimide functionalities. Enzymes such as 
Sortase A or lipoic acid ligase or self-modified enzymes such as intein are utilised for enzymatic labelling. 
Specific tags for instance His tag, the tetracysteine motif or Asp tag are recognized through physical or chemical 




Recently, FERNÁNDEZ-SUÁREZ et al. developed a method for labelling POIs with small fluorescent probes 
by means of lipoic acid ligase (LplA).[13] LplA facilitates the addition of small molecules, which is lipoic 
acid in nature but may be substituted e. g. with functionalized octanoic acid, to an amine side chain 
functionality of the 22 amino acid containing LplA acceptor peptide (LAP). Generally, the labelling is 
enabled by the LplA catalysed reaction with an alkyl azide, which is selectively functionalised with a 
fluorophore bearing a cyclooctyne moiety. In contrast to the previously discussed enzymes, intein is a 
self-modifying enzyme, which was first utilised by MUIR et al. as a tool for protein semisynthesis.[14] To 
introduce intein it is expressed at the C-terminus of the POI. After the formation of a thioester between 
C-terminus of the POI and linked intein, thiol exchange reaction with any cysteine containing moiety 
occurs, to which a fluorophore is attached, affording the desired labelled POI.[15,16] The major 
disadvantage of these described enzymatic labelling methods (see Figure 1: enzymatic) is the disability 
to label a protein of interest in the middle of its sequence.  
 
The tag labelling is an approach, which allows labelling at different sites (N-terminal, C-terminal and 
internal) combined with the introduction of only small artificial sequences, which thereby have a 
smaller influence on the function and activity of POIs, and with high selectivity of the labelling 
process.[3] Of the large diversity of different tags, only the three most commonly utilised will be 
introduced here (see Figure 1: tag). GRIFFIN et al. introduced the cysteine tag (Cys-Cys-X-X-Cys-Cys), 
which is addressed by a biarsenical ligand (such as FlAsH-EDT2 = 4’,5’-bis(1,3,2-dithioarcolan-2-
yl)fluorescein).[17] This bisarsenical ligand is membrane permeant and non-fluorescent until it binds 
with high affinity to the tetracysteine sequence. One of the drawbacks of this method is background 
labelling, which occurs as single or multiple cysteines also interact with these dyes, even though in a 
smaller amount. A second tag technique worth mentioning is the histidine tag, an oligohistidine 
sequence of six histidines or more, which selectively coordinates nickel ions, as discovered by HOCHULI 
et al. in 1987.[18] GUIGNET et al. applied this method for labelling by introducing a fluorescent probe to 
complexes such as Ni(II) nitrilotriacetic acid (Ni(II)NTA).[19] With these complexes genetically encoded 
His tags of membrane proteins are labelled in vivo. Besides the histidine tags, an aspartate tag (Asp-
Asp-Asp-Asp), which coordinates Zn(II) ion is utilised for in vitro and in vivo labelling. OJIDA et al. showed 
a high selectivity and affinity for the binuclear Zn(II)-Dpa (2,2’-dipicolylamine) complex based on a 
tyrosine scaffold, where a fluorophore probe is attached to tyrosine.[20] Comparable to the His tag, this 
method provides a system for the labelling of membrane proteins acting orthogonal to His tags without 
having the disadvantages included by Cys tag labelling.  
 
Another approach, which includes the introduction of small fluorescent probes, but provides covalent 




and either utilises natural occurring amino acids or the introduction of unnatural amino acids. A 
detailed overview of the different bioorthogonal methods, which are applied for chemical labelling is 
given in the following chapter. 
2.2 Chemical labelling – bioorthogonal reactions 
The easiest chemical labelling approach comprises the reaction of activated fluorophores with side 
chains of intrinsic proteogenic amino acids. The amino acids mostly addressed are lysine and cysteine. 
A great number of amine labelling reactions (of either the ε-amino group of lysine or N-terminal amino 
group) are facilitated by the reaction with N-hydroxysuccinimide ester (NHS-ester) activated 
fluorophores (Scheme 2, A). This reaction occurs fast, in high yields and forms a stable amide bond. 
Due to the high occurrence of lysine in almost all proteins, the labelling reaction is not specific enough 
for most systems.[3] In comparison, cysteine is less prevalent and is at a pH range of 6.5-7.5 specifically 
labelled by a MICHAEL addition with maleimide activated fluorophores (Scheme 2, B). At higher pH 
values, unwanted side reactions with amines take place.[21] Labelling reactions with the remaining 18 
proteogenic amino acids have only been minimally exploited, and will not be further discussed here. 
In addition to side chain modifications, the N-terminus is also available for labelling reaction e. g. by 
NATIVE CHEMICAL LIGATION (in the presence of a N-terminal cysteine).[22]  
 
In addition, the introduction of unnatural amino acids for application in bioorthogonal labelling 
reactions is widely utilised. The breakthrough in bioorthogonal chemistry was the development of the 
copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) independently by SHARPLESS et al. and MELDAL 
et al. in 2002 (Scheme 2, C).[23,24] The copper(I) catalyst strongly enhances the reaction of an azide with 
a terminal alkyne. While CuAAC is widely applied in vitro, the cell toxicity of copper(I) minimises its 
applicability in vivo. The strain-promoted azide-alkyne cycloaddition (SPAAC) obviates the need for 
copper(I), by utilising reactive cyclooctyne scaffolds.[25] The drawback of this method is the quick 
reaction of cyclooctyne and its derivatives with cellular nucleophiles, e. g. thiols. The reaction rate of 
CuAAC is enhanced by the introduction of tris(triazolylmethyl)amine ligands (including TBTA and its 
derivatives), which also protect copper(I) from oxidation.[26] Furthermore, BROTHERTON et al. described 
an azide substrate containing an auxiliary ligand (such as picolyl azide) and thereby increasing the 
reaction rate, by directing copper to the azide moiety.[27] By the combination of these techniques, the 





Scheme 2: Overview of chemical labelling techniques frequently applied. A) and B): reactions with natural 
occurring amino acids, C): copper(I)-catalysed azide-alkyne cycloaddition, D): STAUDINGER ligation, E) inverse 
electron demand DIELS-ALDER reaction. 
 
An additional method making use of azide functionality is the STAUDINGER ligation (Scheme 2, D). The 
reaction of an azide with a triaryl phosphine is a popular choice for in vivo labelling owing to its 
selectivity and compatibility with cells and tissues although being slower than most other 
bioorthogonal techniques.[28] Furthermore, DIELS-ALDER cycloadditions are being employed for 
chemical labelling. BLACKMAN et al. described the reaction of tetrazines with trans-cyclooctene 
derivatives in water and cell media, tolerating a broad range of functionalities (Scheme 2, E).[29] As this 
is one of the fastest bioorthogonal reactions so far, it was immediately applied to a number of 
investigations.  
 
In this thesis labelling was performed either directly, meaning the target was labelled (see chapter 6 
“Labelling of cyclic adenosine-3’,5’-monophosphate”), or indirectly, meaning the targets, being ion 
channels in this thesis, were addressed by specific, labelled compounds. In order to address ion 





2.3 Labelling of ion channels using neurotoxins 
Ion channels are pore-forming transmembrane proteins, which are responsible for signal translation 
and propagation in excitable cells, such as muscle or nerve cells. They play key roles in the generation 
and shaping of action potentials.[7] In order to study their localisation and distribution, two major 
methodical approaches have been pursued. The first approach is the application of the patch-clamp 
technique to detect ion currents across membranes, which allows the monitoring of channel activity 
in localised regions of plasma membranes. However, the distribution of ion channels in whole cell 
membranes of living cells cannot be assigned by applying this method.[30] The second approach is 
specific labelling by immunostaining, in which labelled antibodies are applied for the direct imaging of 
specific proteins. Although a number of antibodies for ion channels are commercially available, most 
of these address intracellular epitopes, generating the need for cell fixation and permeabilisation prior 
to labelling experiments. While there are some antibodies on the market addressing extracellular 
epitopes, the selectivity towards specific ion channels is limited due to the high sequence homology 
between the extracellular domains of different ion channels.[31] 
 
These problems are overcome by the implementation of labelled neurotoxins. Neurotoxins, derived 
from animal venoms, are potent tools for distinguishing the various isoforms of channels. Recently, 
toxin labelling was extended from radiolabelling, which has the disadvantage of working with 
radioactivity, to the labelling with fluorophores, which are attached by the application of 
bioorthogonal strategies (described in chapter 2.2). The site-specific introduction of fluorophores has 
already been described for a few toxins, including hongotoxin, stichodactyla toxin, α-conotoxin and 
iberiotoxin.[32–36] These labelled toxins have a broad applicability, e. g. labelled hongotoxin is utilised 
to investigate the localisation of potassium channels in different brain sections.[32] Due to the high 
diversity of different ion channels and their existing subtypes, the need for specific binding toxins 
bearing a fluorescent marker is still great.  
 
This thesis focusses on three major neurotoxins: µ-conotoxin SIIIA, pompilidotoxin and iberiotoxin, 
whose targets are specific ion channels such as voltage-gated sodium channels and large conductance 
calcium- activated potassium channels.  
 
The first targets of this study are voltage-gated sodium channels (VGSCs), which control the flux of 
sodium ions across cell membranes. When the cell interior is at a potential much more negative than 
the exterior (-80 mV), VGSCs are in a closed state. Upon depolarization, e. g. to -40 mV, VGSCs open. 
The resulting sodium influx is the basis of action potential generation and propagation in excitable 




renders the cells refractory for new stimuli. Subsequent de-inactivation makes the channels available 
again.[37] Structurally, VGSCs consist of a core protein (α-subunit), enabling sodium ion permeability, 
and one or more regulatory subunits. Until now, nine mammalian α-subunit isoforms (NaV1.1-NaV1.9) 
are known. Our cooperation partners NEEF and co-workers are interested in visualising sodium 
channels NaV1.2 and NaV1.6, which are mainly expressed in the central nervous system. Up to now, 
there is a long-standing discussion about the local density of these sodium channels in the axon-initial 
segment of pyramidal cells. COLBERT and PAN observed via patch-clamp experiments a low density 
comparable to that of the somatic membrane, whereas immune-histochemistry studies, for instance 
by WOLLNER and CATERALL, suggested a high density.[38,39] To clarify the local density of these channels 
advanced single-molecule imaging can be used. The visualisation of NaV1.2 and NaV1.6 may be 
accomplished by synthesis of labelled neurotoxins that bind specifically to these channels. The toxin 
of choice was µ-conotoxin SIIIA, a 20 amino acid peptide with a rigid structure stabilized by three 
disulphide bridges. The synthesis and labelling will be discussed in chapter 3: “Labelling and caging of 
conotoxin”. Within this topic a caged conotoxin will also be presented, which might be used to further 
investigate sodium channels.  
 
Neurotoxins are also used to influence the gating properties of ion channels. Pompilidotoxin, a small 
linear peptide, slows or abolishes the inactivation of VGSCs. This neurotoxin is less specific than 
µ-conotoxin as it binds to NaV1.1-1.3 and NaV1.6-1.7 although, NaV1.2 and NaV1.6 are the isoforms with 
the highest affinity.[40] However, it is much easier to synthesize and label because of the lack of 
disulphide bridges. The SCHILD research group was interested in a labelled pompilidotoxin to study the 
involvement of VGSCs in odour sensing in olfactory receptor neurons. The synthesis and labelling of 
pompilidotoxin will be discussed in chapter 4: “Labelling of pompilidotoxin”. 
 
Additionally, large conductance calcium-activated potassium channels (also known as big potassium 
channels = BK channels) were targeted. These channels, together with voltage-gated calcium channels 
(VGCCs), are involved in the fine tuning of action potentials in many neurons. Upon depolarization as 
a result of a stimulus, VGCCs are activated. The following influx of Ca2+ further depolarizes the cell and 
the local Ca2+ concentration is increased. This leads to an activation of BK channels congregating with 
VGCCs. The outward flow of K+ repolarizes the cell, resulting in the closing of VGCCs and priming the 
cell for another cycle of oscillation.[41] The involvement of these channels in odour sensing in olfactory 
receptor neurons (ORNs) is being investigated by BAO in the SCHILD research group. Recent studies by 
BAO show a co-localisation of VGCCs and BK channels on the surface of ORNs of Xenopus laevis (see 
Figure 2).[42] In these studies, localisation of VGCCs is accomplished by using Fluo-5F, a fluorescent 




BK channels are visualized by labelling iberiotoxin (Ibtx), a BK channel specific toxin, with Alexa Fluor® 
488 or 546 protein labelling kit. As these kits specifically label amines and Ibtx contains 5 (+1, if the 
N-terminus is free) amine groups, multiple labelling may occur. A quantification study on the number 
of fluorophores per Ibtx reveals that three to four fluorophores are attached to one Ibtx, making a 
further quantification study of BK channels impossible.[42] For a precise quantification of BK channels 
present in VGCC/BK channel clusters mono-labelled Ibtx need to be developed. This will be discussed 




Figure 2: Co-localisation of BK channels and VGCCs (scale = 5 µm). (A) Image of BK channels stained with Alexa 
Fluor® 488 labelled Ibtx. (B) Image after washing for 30 min after staining. (C) Image of VGCCs during 
depolarization stained with Fluo-5F. (D) Images (A) and (C) merged together, arrows indicate co-localisation.[42] 
   





3 Labelling and caging of conotoxin 
 
 
Conotoxins were first isolated and characterized almost four decades ago. Rapidly, they have emerged 
as valuable neuroscience probes and drug leads because of their unparalleled potency and selectivity 
for ion channels and membrane receptors.[43,44] Conotoxins are produced by cone snails together with 
a mixture of other conopeptides to paralyze their prey. Up to now, around 700 species of cone snails 
have been discovered, each of them expressing an extensive variety of conopeptides. This leads to an 
enormous diversity of conotoxins with around 1700 toxins researched so far.[45,46] These toxins act on 
a wide range of ion channels such as voltage-gated sodium-, potassium- and calcium-channels as well 
as ligand-gated ion channels, for instance nicotinic acetylcholine receptors and serotonin receptors.[47] 
Additional targets are the adrenergic receptor and the norephinephrine transporter.[48,49] Having such 
a variety of targets, conotoxins are used to gain further information about them at the 
pharmacological, physiological or structural level.[50–53] Besides, they serve as drug candidates such as 
Prialt®, a -conotoxin, which is the first marine drug approved by the US Food and Drug Administration 
(FDA) having potent and selective calcium channel activity and therefore is used to treat chronic 
pain.[54] 
 
Structurally, conotoxins are mainly small peptides composed of 10 to 45 amino acid residues.[47] They 
contain multiple disulphide bonds and post-translational modifications (PTMs) accounting for the high 
diversity of conotoxins found in nature. The disulphide bonds are important for the structure and 
thereby function of conotoxins as they constrain and define the three-dimensional structure. In vivo 
conotoxins are first translated as a precursor. The N-terminal propeptide then facilitates protein-
disulphide-isomerase (PDI)-catalysed folding of the conotoxin precursor (see Scheme 3). Whether 
posttranslational modification occurs before, concurrent with, or after the formation of disulphide 
bonds is not yet determined.[55] Identified modifications include N-terminal modifications, C-terminal 
modifications, hydroxylation, γ-carboxylation, sulphation, bromination, O-glycosylation, and 
epimerization.[56] In contrast, the in vitro synthesis of conotoxins is more challenging because of a 
missing complex folding apparatus present in vivo.  




Scheme 3: Native folding of the conotoxin precursor. The N-terminal propeptide facilitates binding of PDI 
catalysing the folding process.[55] 
 
3.1 Synthesis of disulphide rich peptides 
Today two approaches are being employed for the synthesis of conotoxins. The first one is using 
recombinant expression in heterologous expression systems such as E. coli which is applied for a 
number of conotoxins.[57–59] Introducing unnatural amino acids, which is sometimes needed for the 
attachment of labels and incorporation of a variety of PTMs, is still a challenging task using 
recombinant expression. Due to the small size of conotoxins a second approach using chemical 
synthesis is applied. This method eliminates undesired (host) protein contamination by the use of 
recombinant expression and facilitates more control over disulphide bridging as well as the 
introduction of modifications.[47] The first step of the synthesis of conotoxins is solid phase peptide 
synthesis (SPPS) using the Boc/Bzl or Fmoc/tBu strategy.[60–63] Difficulties concerning aggregation, 
secondary structure formation, incomplete coupling/Nα-deprotection, and racemisation are 
overcome by using an optimized Boc in situ neutralization protocol coupled with SPPS if necessary.[64] 
The second step of the synthesis is oxidation of cysteine amino acids forming distinct disulphide 
bridges and thereby inducing a folding of the conotoxin. Correct oxidative folding is important for the 
formation of secondary structures such as α-helices, β-sheets and turns which are crucial for receptor 
recognition, potency and selectivity. The number of possible isomers during this step depends on the 
number of cysteine residues present in the peptide explicitly: (2n)!/(2nn!) with n being the number of 
disulphide bonds, resulting in e. g. 15 possible isomers for three disulphide bridges excluding 
topological isomers.[47] Thus far, conotoxins have been known to have five disulphide bridges at the 
most, therefore, correct formation of all disulphide bridges is highly important.[45,46] In the following 
section the oxidative folding will be described using firstly random oxidation of the fully deprotected 
peptide and secondly regioselective oxidation using different protecting groups and strategies. 
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Additionally, chemical modifications will be shown that simplify the synthesis of conotoxins and 
expand their stability. 
3.1.1 Direct oxidative folding 
Direct oxidative folding has the advantage of limited steps, as few, if any, different protecting groups 
need to be applied. As described above either the fully deprotected peptide is used or the cysteine 
residues are protected e. g. using the acetoamidomethyl (Acm) or tert-butylthio (StBu) group. These 
groups are orthogonal to both Fmoc/tBu and Boc/Bzl strategies and thereby purification of the crude 
peptide is possible prior to deprotection of the cysteine residues and oxidative folding. 
Chromatographic purification of peptides containing free cysteine residues may lead to partial 
oxidation, which hinders efficient chromatography.[65] The free cysteine containing peptide is then 
employed for oxidative folding involving several processes namely oxidation, reduction, isomerization 
or scrambling.[66] Oxidative folding is conducted using either disulphide-containing small molecules 
(e. g. oxidized glutathione or cystine), electron accepting reagents (e. g. molecular oxygen or dimethyl 
sulphoxide) or a recently investigated selenoxide reagent.[67,68] Disulphide containing small molecules 
reversibly react with cysteine residues initially forming mixed disulphide species. The rate of this step 
depends on the pKa of the thiol and therefore on the environment of the thiol as well as on the pH of 
the solvent. Afterwards the asymmetric disulphide is attacked by another peptide thiolate generating 
the desired disulphide bridge and correct folding at the same time. In the second approach using 
electron accepting reagents, the first step is oxidation of peptide thiolate to a peptide sulphenic acid 
which is attacked by a second thiolate leading to the formation of the disulphide bridge (see Scheme 
4A).[67] The recently investigated selenoxide reagent 1 reacts with the peptide thiolate to form an 
unstable Se-S-intermediate which is rapidly attacked by another peptide thiolate to form the 




Scheme 4: Oxidative folding using A: disulphide containing small molecules or electron accepting reagents or 
B: recently investigated selenoxide reagent 1.[67,68] 
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In all these methods the disulphide bridge can be formed either intra- or intermolecular dictating the 
need to work under high dilution in order to prevent the formation of oligomeric side products.[67] 
Moreover, an already formed disulphide bridge may be attacked by another peptide thiolate from the 
same molecule, leading to a reshuffling of disulphide bridges.[67] This process allows the formation of 
the more thermodynamically stable disulphide isomers. Random oxidative folding is influenced by 
proximity, reactivity, accessibility and concentration of thiolate groups with accessibility of thiol groups 
to the intermediate species being the most important.[69,70] Additionally, the relative position of 
cysteine residues of peptides determine the kinetic of folding, namely those furthest away from each 
other slow down the folding process the most.[71] In order to obtain the native peptide in good yields 
different conditions have to be tested for each disulphide-rich peptide e. g. changing temperature, 
concentration of the peptide, ionic strength of the solvent, pH, electron-accepting reagent or redox 
species, and folding additives (e. g. surfactants or organic cosolvents).[67] Nevertheless, random 
oxidative folding is mostly applied for natural peptides and has the disadvantage of the formation of 
different disulphide connectivities leading to several products being hard to purify.[72]       
3.1.2 Regioselective oxidation using different protecting groups 
To overcome the problem of having products with different disulphide connectivities, regioselective 
oxidation is employed. Therefore, the peptide is protected with orthogonal protecting groups for each 
disulphide bridge permitting a stepwise formation of cystines. The disulphide bridges are formed 
either on solid support using the pseudo-dilution effect preferring intramolecular disulphide bridges, 
or by a mixture of formation on solid support and in solution, or by forming all disulphide bridges in 
solution applying different protecting groups. During all steps of deprotection and disulphide bridging 
it is highly important to keep a slightly acidic pH to prevent thiol-disulphide exchange reactions leading 
to reshuffling and scrambling of the disulphide bridges.[47]  
 
As the field of different cysteine protecting groups is immense, only an outline of most common 
protecting groups and those utilised in this work is given below (see Table 1). Most of the thiol 
protecting groups employed today are acid sensitive. Hence, Fmoc/tBu rather than Boc/Bzl strategy is 
mostly applied to synthesize fully protected peptides.[73] Only the 2-pyridinesulphenyl (SPyr) protecting 
group is not stable to basic conditions as it activates the cysteine thiol group to facilitate an attack of 
another free thiol.[74] Thus, this protecting group is implemented into peptides after SPPS to prepare 
disulphide linkage. For syntheses of multiple disulphide bridges containing peptides the order of 
cleavage/deprotection of cysteines is highly important. For example the tert-butylthio (StBu) group is 
cleaved reductively, therefore the resulting disulphide bridge has to be formed first, as otherwise 
already formed disulphide bridges will be reduced during this deprotection step. Additionally, 
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sensitivity of deprotected functional groups towards sequential deprotection conditions has to be 
evaluated before considering disulphide bridges formation strategy. For instance, the commonly used 
Acm group is usually cleaved by iodine which possibly leads to an oxidation of methionine, histidine, 
tryptophan, or tyrosine residues, or a shift of Acm towards serine or threonine.[47,75,76] To prevent these 
problems the group of ALBERICIO proposed the new protecting group phenylacetoamidomethyl 
(Phacm) having the same stability as Acm. However, this protecting group is cleaved using the enzyme 
penicillin G acylase (PGA) offering mild deprotection conditions.[77,78] The enzyme is highly specific for 
the phenylacetyl residue, retaining Acm groups during Phacm cleavage.  
   
Table 1: Thiol protecting groups for peptide synthesis.[78–83] 
Protecting group Structure Stability Removal 
Triphenylmethyl (Trt) 
    
base, 
nucleophiles 
diluted TFA/scavenger, I2, 
Ag(I), Hg(II), Ti(III), RSCl 
Dimethoxytrityl (Dmt) 
    
base diluted TFA/scavenger 
Acetoamidomethyl (Acm) 
    
TFA, HF (0 °C), 
base 
I2, Hg(II), Ag(I), Ti(III), RSCl, 
Ph2SO/MeSiCl3 
tert-Butylthio (StBu) 
    
TFA, HF (partial), 
base, RSCl 
RSH, Bu3P, (HOOCCH2CH2)3P 
tert-Butyl (tBu) 
    
TFA, HF (0°C), 
Ag(I), I2 
HF (20 °C), Hg(II), RSCl, 
Ph2SO/MeSiCl3 
2-Pyridinesulphenyl (SPyr) 
    
acid RSH, thiocarboxylic acid, DTT 
Phenylacetoamidomethyl 
(Phacm) 
    
TFA, HF, base penicillin aminohydrolase, 
Hg(II), Ti(III), I2 
4-Methylbenzyl (Mbzl) 
    
TFA, Ag(I), base, 
RSCl 
HF (0 °C), Ti(III), 
Ph2SO/MeSiCl3 
   
The disulphide bridge formation strategies being mostly applied are shown in Table 2. The first 
disulphide bridge is protected using either Trt or StBu offering the possibility to decide whether to 
purify the peptide prior to regioselective oxidation (StBu). Furthermore, the Acm, tBu and Mbzl groups 
are common protecting groups for the 2nd and 3rd disulphide bridge formation. To carry regioselective 
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oxidation to the extreme CUTHBERTSON et al. synthesized an α-conotoxin dimer peptide containing four 
disulphide bridges using Trt, Acm, tBu and Mbzl successively. This is the first example of using four 
distinct protecting groups to produce conotoxin analogues.[84] 
 
Table 2: Common regioselective oxidation protocols for peptides containing 1-3 disulphide bridges using 
Fmoc/tBu strategy.[73] 1Deprotection and cleavage from the resin using TFA. 2I2/AcOH/H2O, Cys(Acm) and 
Cys(Trt) are oxidized in different rates in chloroform, dichloromethane and 2,2,2-trifluorethanol. 3Phosphine-
mediated reductive cleavage. 4DMSO/TFA at rt or PheS(O)Phe/MeSiCl3/TFA. 5DMSO/TFA at 60 °C. 
1st disulphide 2nd disulphide 3rd disulphide 
Trt1 Acm2  
StBu3 Acm2  
StBu3 Trt2 Acm2 
Trt1 Acm2 tBu4 
Trt1 tBu4 Mbzl5 
 
In addition to the influence of employing different protecting groups, the distribution of these groups 
along a peptide sequence strongly affects the outcome of the synthesis.[85,86] Despite the 
regioselectivity of sequentially synthesized disulphide rich peptides the formation of multiple products 
is still possible. For instance, two topological isomers are isolated during the synthesis of enterotoxin 
with the incorrectly folded isomer being completely converted into native conformation using redox 
reagents (e. g. glutathione). The folding of the topological isomer appears to be regulated by the last 
disulphide bond formation defining the conformation of final product which is either a right-handed 
(native isomer) or left-handed spiral (topological isomer).[87,88] In addition to using different protecting 
groups regioselectivity is reached by the introduction of modifications, e. g. selenocysteines. This topic 
will be discussed further in the next chapter.  
3.1.3 Synthetic modifications of conotoxins 
Due to the drug potential of conotoxins many modifications are investigated to increase their stability 
and activity. Until now the peptidomimetic strategy, developing a rational design of organic scaffolds 
and thereby topographically mimicking key binding elements of native conotoxins, resulted in losses 
of activity.[89] Another commonly used technique is to slightly alter native conotoxins to improve their 
properties as drugs (see an overview in Figure 3). Owing to high lability of cystine frameworks to 
reducing environment disulphide isosters, such as diselenide, dicarba, cystathionine as well as lactam 
bridges were introduced instead of disulphide bridges.[90–93] Especially the selenoconotoxins are being 
widely used as these analogues showed an improved stability to reductive conditions.[94]   
 




Figure 3: Overview of synthetic modifications applied to conotoxins. Unstable residues such as methionine 
(M), which is easily oxidized in nature, are substituted in modified peptides. a) cystine isosters (e. g. 
selenocystine) b) inversion of selected residues c) side chain modification d) N- and C-terminal capping 
e) backbone cyclization f) truncation of N- and C-termini.[95] 
 
Another way of increasing stability is sequence modification. Several amino acids such as methionine 
or arginine residues are easily degraded (e. g. by oxidation); hence, these residues are being replaced 
if possible.[96,97] Additional attempts to reduce proneness towards proteolytic degradation are the 
substitution of L- versus D-amino acids, being employed for -conotoxins MVIIA and CVID.[98,99] Further 
approaches include side chain modifications such as adding lipid tags or introducing additional post-
translational modifications either on the side chains or the C- and N-termini improving bioavailability 
and stability.[100–104] Besides, the structure is simplified e. g. by inserting flexible spacer as backbone 
replacement or truncation of the peptide sequence.[105–107] The stability of conotoxins towards 
degradation may be improved by cyclization joining the C- and N-termini using amino acid linker.[108,109] 
To conclude, many modifications of conotoxins are known today to increase stability of these peptides. 
For every peptide evaluations have to be made of the influence on potency, as some modifications 
might reduce, increase or modulate the affinity towards special targets. 
3.2 Synthesis of labelled µ-conotoxin SIIIA 
The main target of this thesis was the synthesis of labelled µ-conotoxin SIIIA (short µ-SIIIA) which is 
one of the µ-conotoxins selectively inhibiting voltage-gated sodium channels (VGSC). VGSCs are 
responsible for the influx of sodium ions during action potentials.[110] The recent determination of 
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crystal structures of bacterial VGSCs offers the opportunity for simulations of mammalian VGSCs 
leading to molecular dynamics studies of binding of µ-conotoxins.[111–115] Exemplarily, the docking of 
µ-GIIIA to VGSC NaV1.4 directly blocking the pore of the channel is shown below (Figure 4). The outer 
pore of VGSCs mostly consists of electronegative residues such as aspartic acid or glutamic acid, which 
are addressed by positively charged residues like lysine or arginine of the µ-conotoxin. In contrast to 
potassium channels where one lysine is sufficient to block the channel at least two basic residues are 
required to achieve the same in sodium channels.[116] In comparison to non-peptidic toxins blocking 
the VGSCs, like saxitoxin (STX) or tetrodotoxin (TTX), µ-conotoxins distinguish between the different 
subtypes of VGSCs and are modifiable by introducing different amino acid residues thereby inducing 
different selectivities.[117–119] This difference in selectivity is due to the fact that the binding sites of TTX 
and µ-conotoxins overlap only partially and more residues of the VGSCs are involved in the binding of 
µ-conotoxins (additional to the four residues shown here for µ-GIIIA).[119] Furthermore, ZHANG et al. 
discovered conotoxin µ-KIIIA and TTX binding simultaneously to VGSC NaV1.2 with µ-KIIIA having higher 
off-rates in presence of TTX due to a repulsive interaction of positively charged residues offering even 
further applications for labelled µ-conotoxins.[120]  
 
                    
Figure 4: Docking of conotoxin µ-GIIIA (purple) to a homology model of NaV1.4 (grey): side view (left) and top 
view zoomed in on the binding site (right). The interacting residues of µ-GIIIA (R13, K11, K16) and NaV1.4 (E403, 
E758, D1241, D1532) are presented as sticks (PDB file provided by MAHDAVI et al.).[116] 
 
One of the smallest conotoxins and thereby a good target for labelling is conotoxin µ-SIIIA, comparable 
with µ-KIIIA it displays a strong selectivity towards mammalian neuronal sodium channel NaV1.2 
leading to nearly irreversible blocking of the channel. In addition, it blocks skeletal muscle subtype 
NaV1.4 (reversible blocking) and neuronal NaV1.6 (partially reversible).[121] µ-KIIIA and µ-SIIIA differ only 
in a few residues, with µ-SIIIA having four additional residues. These findings implicate that the 
additional residues do not disturb the overall activity and might be easily used for modification and 
labelling.  
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3.2.1 Structural and functional analysis of µ-conotoxin SIIIA 
Conotoxin µ-SIIIA is a short conotoxin, 20 amino acids in length, containing three posttranslational 
modifications: N-terminal cyclization forming pyroglutamate, C-terminal amidation, and disulphide 
bridging. Pyroglutamate (pGlu) causes N-terminal blockage of peptides protecting them from 
enzymatic digestion by exopeptidases.[122] Comparable to the N-terminal pyroglutamate the C-terminal 
amidation affects the overall isoelectric point and overall charge state (net charge of µ-SIIIA = +2), 
which may influence three-dimensional structure and is important for binding to the negative surface 
of VGSC.[123,124] Additionally, amidation protects µ-SIIIA against carboxypeptidase activity.[125] Three 
disulphide bridges are formed which are buried in the core of the molecule. The structure is further 
defined by an α-helix including residues 11-16 determining the arrangement of side chains along this 
motif (see Figure 5). 
 
            
 
Figure 5: Average ribbon structure of µ-conotoxin SIIIA (top): The α-helical motif is seen across residues 11-16. 
The three disulphide bonds are highlighted in yellow. The important residues for the affinity are highlighted 
in purple. See BMRB accession code 20025.[126] One letter code of µ-conotoxin SIIIA (3) (bottom): Z = pGlu, the 
C-terminus is amidated. 
 
The key binding determinants are distributed across this motif (Lys11, Trp12 and Arg14) and along it 
(Arg18). Each is contributing similarly to the binding affinity of µ-SIIIA.[126] Furthermore, substitution of 
His16 by alanine leads to a strong decrease in affinity, with αH-chemical shifts changes indicating 
perturbation of backbone structure.[126] YAO et al. conducted further temperature dependent 
backbone dynamic calculations revealing high flexibility of pGlu1, Asn2 and Ser9.[127] Additionally, a 
substitution of Asn5, Ser9 and Ser10 of the related µ-KIIIA does not change blockage of the 
channels.[121] 
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3.2.2 Modifications of µ-conotoxin SIIIA and their influence on activity 
In order to develop possible positions for labelling preliminary considerations have to be made based 
on already existing modifications known for µ-SIIIA and related compounds (µ-KIIIA, truncated µ-SIIIA 
missing pGlu1, Asn2, Gly6 and Gly7; and µ-SIIIB, differing in two residues: Lys14 and Gly15 compared 
to Arg14 and Asp15 for µ-SIIIA).[45,46] Many investigations have been carried out to improve the 
synthesis of µ-SIIIA and related compounds. To stabilize the structure of µ-SIIIA and enhance the 
oxidative folding rate WALEWSKA et al. and STEINER et al. installed diselenide bridges instead of 
disulphide bridges replacing either C3-C13, C4-C19 or C8-C20 disulphide bridge. The oxidative folding 
is enhanced using this method but a small decrease in overall blocking is observed.[128,129] Comparable 
results are obtained for modified µ-KIIIA, removing one disulphide bridge and substituting another 
disulphide bridge with a diselenide bridge does not lead to an enhanced affinity.[130,131] In contrast, 
deletion of one single disulphide bridge leads to significantly larger off-rates when compared to native 
µ-KIIIA.[132] Besides, disulphide depletion and N-terminal truncation of µ-KIIIA stabilizing the α-helical 
motif by one lactam bridge results in similar structures and good binding affinities for the lactam 
between positions Asp9 and Lys13. However, the high binding affinities of natural µ-KIIIA are not 
reproduced.[133] Another approach, namely backbone prosthesis, was applied by GREEN et al. to µ-SIIIA 
substituting non-essential residues such as the two Gly residues in the first loop or the N-terminal Asn 
and pGlu by non-peptidic spacers like amino-3-oxapentanoic acid or 6-aminohexanoic acid. Structural 
analysis reveals similar structural conformations of these analogues and activity essays are 
promising.[105] In contrast, replacing pGlu with Glu in µ-SIIIB reduces affinity of NaV1.2 compared with 
natural µ-SIIIB.[134] [pGlu1Arg]-µ-SIIIA has slightly increased VGSC affinity, with a change in selectivity 
from NaV1.2 to NaV1.4. SCHROEDER et al. synthesized even more N- and C-terminal extended µ-SIIIA and 
µ-SIIIB. C-terminal elongation of µ-SIIIA using Ala residues as well as N-terminal elongation of µ-SIIIB 
using Glu does not change the potency strongly. Furthermore, an increase in potency and neuronal 
selectivity is seen for µ-SIIIA substituting Asp15 by an alanine.[134] Based on this finding AKONDI et al. 
reengineered loop 1 using the [Asp15Ala]-mutant altering the overall charge and size of this loop. An 
increase in affinity is seen for the [Asn5Lys]-mutant being truncated at the N-terminus. Additionally, 
the deletion of Gly6 does not influence the affinity strongly.[135]  
 
STEVENS et al. synthesized a number of very small (13 residues) µ-KIIIA/µ-BuIIIC analogues having the 
first disulphide bridge and one of the Ser residues deleted. Even though an α-helix is not observed, the 
analogue has nearly similar potency as the native peptide.[136] A totally different approach is the design 
of organic scaffolds topographically mimicking key binding elements of native peptides, which is 
employed for µ-KIIIA.[89] BRADY et al. synthesized a diketopiperazine carboxamide scaffold 
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functionalized with Lys, Trp and His and a benzamide functionalized twice with Arg; both showing only 
very small sodium channel affinities.[89,137]  
3.2.3 Synthesis and labelling of alkyne modified µ-conotoxin SIIIA 
Following this detailed analysis of µ-conotoxin analogous a strategy for labelling µ-SIIIA was proposed. 
The sequence of native µ-SIIIA contains acid, amine and thiol functionalities, hence, introduction of a 
label could only be accomplished employing an orthogonal reaction or an elaborate protecting 
scheme. As previously described (see section 2.2) the copper(I)-catalysed azide-alkyne cycloaddition 
(CuAAC) provides this kind of orthogonally. Following this approach an azide or alkyne moiety should 
be introduced into the peptide. As a result of the introduction of an azide into peptides might possibly 
be the reduction to the corresponding amine during cleavage, an alkyne moiety should be 
incorporated into µ-SIIIA.[138] As truncated analogues of µ-SIIIA mainly show smaller affinities and 
adding residues to already very short analogues may have a great impact on overall structural 
properties, native µ-SIIIA should be modified bearing an alkyne moiety. As described in literature, the 
alkyne moiety was introduced by side chain propargylation of Boc protected serine 4 using sodium 
hydride and propargyl bromide, followed by Boc-deprotection and Fmoc-protection of 5 to form 
Fmoc-L-Ser(2’-propyne)-OH (6) in good yields (see Scheme 5).[139–141] Providing an alkyne in a position 
far away from the backbone should allow CuAAC to take place even in folded peptides. Additionally, 
the polar side chain of serine prevents formation of aggregates during peptide synthesis.[141] 
 
 
Scheme 5: Synthesis of Fmoc-L-Ser(2’-propyne)-OH (6). 
 
By analysing µ-SIIIA analogous possible modifiable positions were ascertained. As mentioned above 
the C-terminal and N-terminal extensions of µ-SIIIA/B do not change the ability to bind to VGSCs.[134] 
Additionally, Gly6 and Ser9 are removed without a strong decrease in affinity.[135,136] Therefore, four 
peptides were postulated for synthesis (7-10, see Figure 6).   
 




Figure 6: Alkyne modified peptides postulated for synthesis. Z = pGlu, the C-terminus is amidated. 
 
First of all, direct oxidative folding was performed as described before (see 3.1.1) using trityl protecting 
group for cysteine residues. As described by BULAJ et al., the linear precursor was synthesized on rink 
amide MBHA resin as solid support preloaded with Fmoc-L-Cys(Trt)-OH according to Fmoc based SPPS 
protocols providing a C-terminal amide after cleavage.[110] Artificial amino acids 
Fmoc-L-Ser(2’-propyne)-OH (6) as well as H-L-pGlu-OH were coupled using lower temperatures and 
longer reaction times, as racemisation rates were unknown. Initial occurrence of aspartimide 
formation (m/z = -18) was circumvented by adding 0.1 M 1-hydroxybenzotriazole (HOBt) to the 
deprotection solution.[142] The racemisation of cysteine and histidine was suppressed using lower 
reaction temperatures (50 °C) during coupling. This reduces the amount of D-amino acid from >8.00% 
to 1.59% for histidine and >3.96% to 3.16% for cysteine respectively.[143] Linear [Gly6Ser(2’-propyne)]-
µ-SIIIA and [Ser9Ser(2’-propyne)]-µ-SIIIA precursor were obtained in good yields and purity. Direct 
oxidative folding of native µ-SIIIA using different reagents has been covered in literature. The following 
methods were tested for the alkyne modified µ-SIIIA analogues: 
 
 Linear µ-SIIIA was dissolved in high dilution in aqueous solution of 0.1 M Tris/HCl solution, 1 mM 
oxidized and 1 mM reduced glutathione and 0.1 mM EDTA (pH 7.5). 
 Linear µ-SIIIA was dissolved in high dilution in aqueous NH4HCO3-solution (pH 9.1). 
 Linear µ-SIIIA was dissolved in high dilution in aqueous NH4HCO3-solution, 1 mM oxidized and 
1 mM reduced glutathione and 0.1 mM EDTA (pH 7.1). 
 Linear µ-SIIIA was dissolved in high concentrations in an ionic liquid. 
Labelling and caging of conotoxin 
 
25 
The first method was described by GREEN et al. and STEINER et al. testing different reaction times, 
pH-values, molar ratios of glutathione in the oxidized and reduced form and different 
temperatures.[105,144] The high dilution is necessary to prevent polymerization and aggregation. Herein, 
the described conditions were used differing reaction times and work-ups. The reaction mixtures were 
either directly subjected to freeze-drying or water was removed using rotary evaporator. Diverse 
efforts were made to desalinate crude products using either reverse phase column chromatography 
or dialysis membranes with different pore sizes (molecular weight cut of: 100-500 D or 500-1000 D). 
Albeit obtaining small amounts of desired product HPLC diagrams showed a scrambling indicating 
formation of multiple disulphide bond and topological isomers. The second method was previously 
performed by AVRUTINA to fold cystine-knot microproteins and the third method was a combination of 
the first and second method.[145] An advantage of using ammonium bicarbonate as buffer solution is 
its removability by freeze-drying making extensive desalination steps superfluous. By these two 
methods no product was obtained. Applying the fourth method renders the need to use high dilution 
obsolete as MILOSLAVINA et al. found 1-ethyl-3-methylimidazolium acetate [C2mim][OAc] to be able to 
solubilise and stabilise secondary structure by providing hydrogen bonds between anions of 
imidazolium salt and hydroxyl groups of the solute.[146] Thereby, the formation of correctly folded 
product is favoured and amount of misfolded peptides reduced. Even though correct mass was 
detected, a separation of ionic liquid from the peptide was impossible. A recent investigation by HEIMER 
et al. scaling up the previously performed reaction resulted in a significant loss of inhibiting effect on 
NaV1.4 channels, attributed to an adherence of ions from [C2mim][OAc] to peptides, with connectivity 
of disulphide bridges and HPLC profile being in accordance to conventionally oxidized µ-SIIIA 
versions.[147] Due to the formation of multiple isomers using glutathione in Tris buffer another strategy 
was applied for the synthesis of labelled µ-SIIIA. Although previously described regioselective oxidation 
(see section 3.1.2) of three disulphide bridges might be time-consuming it has the advantage of 
selectively formed bridges reducing the amount of different isomers to a few topological isomers.[148]  
 
Regioselective oxidation of µ-SIIIA was based on a strategy proposed by LINDNER et al. in 2012 (see 
Scheme 6).[81] Peptides are synthesized on 2-chlorotrityl chloride resin using RAMAGE-linker providing 
C-terminal amides.[149] Thereby, peptides can be cleaved from the resin using very low acidic conditions 
before deprotecting side chain protecting groups. As the first disulphide bridge usually is the hardest 
to form a method previously exercised in interchain disulphide bridge formation is used to increase 
the yield; the first cysteine residue is activated for subsequent reaction with the second cysteine.[65] 
Thiols are activated by introducing an electron-withdrawing substituent e. g. 2-thiopyridine. This 
residue is introduced using 2,2’-dithiodipyridine. In order to have a good activation of thiols using 
mixed disulphides a deactivated leaving group is highly important to prevent thiol/disulphide exchange 
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reactions; in the case of SPyr the leaving group is 2-thiopyridine which immediately tautomerizes to 
inactive 2-thiopyridone.[150,151] As the cysteine activation group SPyr is not stable during coupling 
conditions StBu is introduced into the peptide being cleaved of using 2-mercaptoethanol followed by 
a reaction with 2,2’-dithiodipyridine. After cleavage from the resin the fully protected peptide 
containing activated thiol then reacts with a second thiol, which has been Dmt protected beforehand. 
Following the formation of the first disulphide bridge, all protecting groups are deprotected including 
Trt protected cysteine. LINDNER et al. proposed a one-pot iodine oxidation forming the second 
disulphide bridge, deprotecting Acm-groups and forming the third disulphide bridge.[81] The 
advantages of this regioselective strategy by LINDNER et al. are: 
 
 High dilution during formation of the first disulphide bridges prevents polymerization reaction. 
 Unprotected peptide containing one disulphide bridge and the following steps are handled in 
acidic medium preventing shuffling of the disulphide bridges. 
 Regioselective disulphide bridge formation in acceptable yields. 
 
 
Scheme 6: Regioselective approach proposed for µ-SIIIA as described by LINDNER et al.[81] 
 
As Fmoc-L-Cys(Dmt)-OH (11) is not commercially available, it was synthesized in two steps following a 
procedure of LINDNER et al. (see Scheme 7).[81] Unprotected cysteine (12) was treated with 
4,4’-dimethoxytrityl chloride to form a thioether (13) followed by N-terminal Fmoc-protection using 
Fmoc-Cl. Flash chromatography was carried out quickly and without acid to prevent Dmt-deprotection 
on the slightly acidic silica yielding the product (11) in good yields. 
 




Scheme 7: Synthesis of Fmoc-L-Cys(Dmt)-OH (11). 
 
2-Chlorotrityl chloride resin was then preloaded with the Fmoc protected RAMAGE-linker using DIPEA 
for activation. An excess of 2-chlorotrityl chloride resin, reduced reaction times and capping with 
methanol and DIPEA were necessary to reduce the loading density from 1.5 mmol/g for 2-chlorotrityl 
chloride resin to 0.30-0.40 mmol/g of preloaded resin. A low loading density was used to prevent 
aggregation during solid phase peptide synthesis. After Fmoc deprotection the first amino acid 
Fmoc-L-Cys(Trt)-OH was coupled using N,N’-diisopropylcarbodiimide (DIC) and HOBt, thereby 
preventing base-catalysed racemisation during activation and coupling of Trt protected cysteine.[152,153] 
Furthermore, linear C-terminal modified µ-SIIIA-[Ser(2’-propyne)] precursor 14 was synthesized 
according to Fmoc based SPPS protocols reducing the temperature as 2-chlorotrityl chloride resin is 
sensitive to high temperatures. As previously described the StBu protecting group was cleaved by 20% 
2-mercaptoethanol as the reducing agent. Subsequent reaction with 2,2’-dithiodipyridine yielded the 
activated disulphide bridged Cys(SPyr) derivative 15. Cleavage from the resin was performed using 
mild acidic conditions yielding 16 (see Scheme 8).  
 




Scheme 8: First deprotection steps performed on linear µ-SIIIA-[Ser(2’-propyne)] precursor 14: StBu 
deprotection was followed by activation of the free thiol to Cys(SPyr) and subsequent cleavage from the resin 
yielding peptide 16. Z = pGlu. 
  
Further acidification under high dilution using low concentrations of TFA yielded Dmt deprotected 
peptide which was transferred to a solution of triethylamine (10%) to form the first disulphide bridged 
peptide 17 by deprotonating the free thiol group which then reacted with activated Cys(SPyr). After 
precipitation the crude product was directly deprotected utilising triisopropylsilane (TIS) and water as 
scavengers obtaining crude peptide 18 in an overall yield of 64% (see Scheme 9). Neither deletion 
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sequences nor disulphide depleted side products were detected by mass analysis. The Acm protecting 
group remained stable under these conditions. 
 
 
Scheme 9: Formation of the first disulphide bridge of µ-SIIIA-[Ser(2’-propyne)] followed by deprotection of all 
side chain protecting groups except the Acm group. Z = pGlu, the C-terminus is amidated. 
 
The one-pot oxidation proposed by LINDNER et al. for native µ-SIIIA did not lead to any product 
formation in the following steps of disulphide formation, Acm deprotection and disulphide formation 
of Acm deprotected thiols.[81] Therefore, a stepwise procedure was undertaken firstly to form the 2nd 
disulphide bridge and secondly to deprotect the Acm groups and to generate the 3rd disulphide bridge. 
Alternatively to oxidation by atmospheric oxygen being a relatively slow process or by mild oxidizing 
agents such as potassium ferricyanide which may lead to side products such as oxidation of Met and 
Trp residues and has an additional step of removing the oxidizing reagent, DMSO-promoted oxidation 
is frequently utilised.[65,154,155] It can be applied over an extended pH range of 1 to 8.[156] In general, 
acidic media induces faster oxidation rates and it also prevents shuffling of already formed bridges. 
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However, low pH (pH < 3) accelerates oxidation of other side chains, such as methionine. Following a 
procedure of TAM et al. disulphide formation to peptide 19 was carried out at pH 6 with 20% DMSO in 
high yields (see Scheme 10).[156]  
 
 
Scheme 10: Formation of the second and third disulphide bridge of µ-SIIIA-[Ser(2’-propyne)] (7). Z = pGlu, the 
C-terminus is amidated. 
 
For the deprotection of Acm groups and simultaneous disulphide bridge formation a method described 
by LINDNER et al. was first applied utilising iodine in a solution of acetic acid/water with anisole as 
scavenger for 2 h leading to no product formation.[81] As oxidation by iodine is known to cause serious 
side reactions on several amino acids such as Tyr, Met, His and Trp extensive efforts have been made 
in the past to optimize reaction conditions.[75] To prevent side reactions with Trp residues 
Ac-L-Trp-OMe is added as scavenger.[157,158] Additionally, disulphide exchange reactions may occur by 
an electrophilic attack of sulphenyl iodide, which usually reacts with free cysteines to produce the 
desired disulphide, on preformed disulphides. This will lead to shuffling und scrambling of disulphide 
bridges. Although, KAMBER et al. described this reaction to be a minor side reaction (5% side product 
after 4 h) being reduced by reduction of reaction time.[75] In this thesis, additional tests were performed 
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to analyse the stability of the alkyne moiety to the conditions of LINDNER et al. taking the Fmoc 
protected amino acid as starting material which resulted in the formation of diiodated product. To gain 
knowledge whether Acm deprotection and disulphide formation or iodination occurred first or if these 
reactions happened at the same time, LC-MS was performed. Thus, the reaction mixture (acetic 
acid/water, Ac-L-Trp-OMe, iodine) was quenched with aqueous ascorbic acid solution after 0, 5, 10, 
20, 30, 40, 50 and 60 min. The desired product 7 was already seen when the reaction mixture was 
quenched directly after iodine addition (0 min). After 5 min the starting material 19 was consumed and 
first traces of iodated side product were seen after 20 min. Therefore, this reaction was carried out for 
10 min to have a complete conversion to the desired product 7.  
 
In a second approach deprotection was analysed using silver(I) trifluoroacetate followed by oxidation 
with 10% DMSO in 1 M hydrochloric acid. By this approach the formation of oxidised and iodated 
products should be minimised. With this method no product was obtained, possibly due to problematic 
destruction of the silver-peptide complex using DMSO in hydrochloric acid as described by HARRIS 
et al.[159] Other possible methods to release peptides would also reduce already formed disulphide 
bridges.  
 
Therefore, the previously described iodine method, followed by a direct purification of the quenched 
reaction mixtures on preparative HPLC, was utilised. HPLC purification yielded three main products 
having the same mass but different retention times (see Figure 7). Due to the regioselective formation 
of disulphide bridges different products could only be topological isomers (see section 3.1.2). Because 
of small amounts of obtained product no NMR analysis was performed which would give detailed 
information about the structure of each isomer. Instead, collected peaks were directly given for 
analysis by whole-cell patch-clamp but were not measured yet. 
 
 
Figure 7: HPLC trace of crude µ-SIIIA-[Ser(2’-propyne)] (7). Three topological isomers (marked by an arrow) will 
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The whole sequence of reactions was repeated to synthesize [pGlu1Ser(2’propyne)]-µ-SIIIA (8). The 
first and second disulphide bridged peptide was obtained in good yields (1st 46%, 2nd 67%) but 
formation of the third disulphide bridge gave four topological isomers. Two of them could be purified 
in an adequate amount and inhibition rates are now being measured using patch-clamp. 
 
[Gly6Ser(2’-propyne)]-µ-SIIIA (9) was prepared using the same reaction method yielding 75% crude 
product for the formation of the 1st disulphide bridge and 98% crude product for the 2nd disulphide 
bridge. Formation of the 3rd disulphide bridge yielded three topological isomers which were analysed 
using patch-clamp experiments1. Inhibition studies were conducted at 1 µM in HEK293 cells that 
expressed voltage dependent sodium channels from rat, rNaV1.2. The two DNA-plasmids encoding 
green fluorescent protein (GFP) and rNaV1.2 (ratio 1:3), respectively, were delivered into cells by 
electroporation. During inhibition tests cells were held at -60 mV. Every 10 s sodium channel 
availability was monitored with a pulse, consisting of a brief hyperpolarization to -100 mV and a 
depolarization to 0 mV. Maximal block of sodium current observed for [Gly6Ser(2’-propyne)]-µ-SIIIA 
(9) was 90% (see Figure 8). The other topological isomers showed no visible inhibition.  
 
Therefore, labelling was performed with this isomer. As pure peptide was only obtained in yields of a 
few nanomoles, labelling studies were initially made with one of the isomers formed during direct 
oxidative folding. After consulting with the ENDERLEIN research group Alexa Fluor® 647 azide was used 
as the fluorophore. CuAAC was investigated utilising different methods. In comparison to CuAAC using 
small molecules CuAAC with peptides generates several problems as prolonged reaction times are 
needed. To preserve catalytic active copper(I) species during long reaction times reactions must be 
conducted under exclusion of oxygen and reducing agent, furthermore, copper (I) stabilizing agents 
such as tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) need to be applied.[141] First of all a 
method by CORTEKAR, namely using copper(I) (as copper(I) iodide (CuI) or copper(I) iodide-triethyl 
phosphite (CuIP(OEt)3)) together with TBTA and 2,6-lutidine in DMF to couple cysteine knot 
microproteines to cyclic β-peptides, was tested.[141]    
 
                                                          
1 All patch-clamp experiments of µ-conotoxin derivatives were conducted by TING WANG, PhD student in the BCCN 
group (Biophysics of neural computation), supervised by ANDREAS NEEF. 




Figure 8: HPLC trace of crude [Gly6Ser(2’-propyne)]-µ-SIIIA (9). Three topological isomers were analysed by 
whole-cell patch-clamp (block levels of each isomer is assigned with an arrow). 
  
Reactions of modified, folded conotoxin and fluorophore using these methods were analysed after 3, 
4 and 5 days by LC-MS showing no product formation. Furthermore, these reaction conditions were 
unsuccessfully applied to the reaction of Fmoc-L-Ser(2’propyne)-OH (6) with the fluorophore. As these 
shortcomings might also be due to misfolding of peptides, which might reduce accessibility of alkyne, 
or solubility problems in case of the single amino acid, further CuAAC studies were made on 
[Gly6Ser(2’-propyne)]-µ-SIIIA (9) (90% block). The following methods for CuAAC were investigated to 
attach Alexa Fluor® 647 azide or Alexa Fluor® 647 picolyl azide, respectively:   
 
 Copper(I) iodide, sodium ascorbate in DMF. 
 Copper(II) sulphate pentahydrate, ascorbic acid, ethylenediaminetetraacetic acid (EDTA) in 
phosphate buffer. 
 Pentamethylcyclopentadienylbis(triphenylphosphine)ruthenium(II) chloride in dioxane. 
 Click-iT® Plus Alexa Fluor® 647 Picolyl Azide Toolkit including Alexa Fluor® 647 picolyl azide, 
copper(II) sulphate pentahydrate, copper protectant and reaction buffer. 
 
The first method was recently used by PANSE linking two different peptide strands together having 
alkyne and azide moieties.[160] Due to the fact that thiols have a high affinity for copper two other 
methods were tested (2nd and 3rd in the list). The second method was utilised by LI et al. for linkage of 
azide modified bovine serum albumin (BSA, containing 17 disulphide bridges) to alkyne modified 
monomethyl poly(ethylene glycol) and the third method included employment of a ruthenium catalyst 
leading to 1,5- instead of 1,4-disubstituted 1,2,3-triazoles.[161,162] In contrast to CuAAC ruthenium(II)-
catalysed alkyne-azide cycloaddition (RuAAC) allows a wide range of alkynes and is even performed 
with internal alkynes. The fourth method investigated was to utilise an activated azide, namely picolyl 
azide, containing an internal copper-chelating moiety, which raises the effective copper concentration 
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at the reaction side.[163] As these four methods were unsuccessful a 5th method was investigated: the 
use of DIPEA to overcome difficulties forming the active copper acetylide complex (see Scheme 11). 
Addition of base to increase formation of copper acetylide complex is usually applied in case of 
reactions in organic solvents, where this formation is unfavourable and deprotonation is required.[164] 
Recently, KOLMAR et al. described a method for CuAAC using DIPEA in water as well, which was 
employed herein.[165]   
 
 
Scheme 11: Synthesis of labelled [Gly6Ser(2’-propyne)]-µ-SIIIA 20 by addition of DIPEA. Z = pGlu, the 
C-terminus is amidated. 
 
After two days the formation of labelled [Gly6Ser(2’-propyne)]-µ-SIIIA 20 was seen albeit incomplete 
(see Figure 9). Due to small amounts of starting material an optimization of reaction conditions were 
not done, the alkyne was recovered and the reaction repeated.   
 
 




Figure 9: HPLC traces (intensity at 650 nm and 215 nm) of crude reaction mixture of Alexa Fluor® 647 labelled 
[Gly6Ser(2’-propyne)]-µ-SIIIA (20) (90% block). 
 
Labelled [Gly6Ser(2’-propyne)]-µ-SIIIA 20 was analysed using patch-clamp experiments as 
aforementioned. Depolarization-activated sodium currents were measured before and after toxin 
application showing a strong decrease in sodium current within seconds (see Figure 10). 
 
 
Figure 10: Inhibition of rNaV1.2 by Alexa Fluor® 647 labelled [Gly6Ser(2’-propyne)]-µ-SIIIA (20). Superimposed 
depolarization-activated sodium currents in the absence and presence of labelled toxin. HEK293 cells were 
held at -60 mV; every 10 s sodium channel availability was monitored with a pulse (hyperpolarisation 
to -100 mV and depolarisation to 0 mV). Application of 1 µM toxin induces a decrease in sodium channel 
current.   
 
[Ser9Ser(2’-propyne)]-µ-SIIIA (10) was synthesized following the previously described method 
obtaining the 1st disulphide bridge in 72% (crude peptide) and the 2nd in 97% yield (crude peptide). 
Synthesis of the 3rd disulphide bridge yielded three topological isomers which were analysed by patch-
clamp experiments. Maximal block of sodium current (85%) was observed for the isomer having a 

























































Labelling and caging of conotoxin 
 
36 
products (see Figure 11 (left)) having the same mass (analysis by MALDI). These were separated, 
obtained in good purity (see Figure 11 (right)) and will be analysed by patch-clamp experiments. 
 
 
Figure 11: HPLC traces of crude reaction mixture (left) and purified products (right) of Alexa Fluor® 647 labelled 
[Ser9Ser(2’-propyne)]-µ-SIIIA (21) (85% block) (for the structure of 21 see Figure 27). 
 
To conclude, labelled µ-SIIIA was synthesized by introducing an amino acid modified with an alkyne 
moiety into the peptide sequence, which was subsequently labelled with a fluorophore bearing an 
azide moiety. Additional patch-clamp experiments are currently under investigation to further analyse 
the properties of labelled µ-SIIIA and imaging experiments will be conducted in near future.  
3.2.4 Synthesis of thiol modified µ-conotoxin SIIIA 
Owing to small yields in forming the last disulphide bridge using an alkyne moiety another method was 
executed introducing a further cysteine, which might later on react with a maleimide activated 
fluorophore, protected by the Mbzl group (see chapter 3.1.2), which might be cleaved after the three 
disulphide bridges were formed. The Mbzl group is often used in Boc/Bzl strategy to protect cysteine. 
The group is usually cleaved by hydrofluoric acid (HF) but can also be cleaved using milder conditions, 
e. g. tetrafluoroboric acid in triflouroacetic acid or hydroboric acid in acetic acid eliminating the need 
of special HF apparatuses.[166–168] Mbzl protected cysteine was introduced as beforehand in Gly6 
position and alternatively an N-terminal polyethylene glycol (PEG) linker was utilised to further attach 
one Mbzl protected cysteine at the N-terminus directing away from the active binding site. In contrast 
to N-terminal elongated alkyne modified µ-SIIIA 8 the N-terminal pGlu was preserved, to protect 
peptides from proteolytic digestion. The linear precursor of [Gly6Cys(Mbzl)]-µ-SIIIA 22 was synthesized 
using previously described method, followed by sequential synthesis to the mono- and two-disulphide 
bridge containing peptide 23 and 24, in good yields. In the absence of an alkyne moiety quenching was 
unnecessary during the last step, therefore, it was conducted for a prolonged time and peptide 25 was 
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applied in the synthesis of N-terminal elongated peptide 26 (see Figure 12). In comparison with alkyne 
modified µ-SIIIA several topological isomers were seen on HPLC.  
 
 
Scheme 12: Synthesis of [Gly6Cys(Mbzl)]-µ-SIIIA (25). Z = pGlu, the C-terminus is amidated. 
 




Figure 12: Synthesized N-terminal elongated Cys(Mbzl) modified µ-SIIIA 26. Z = pGlu, X as described, the 
C-terminus is amidated. 
 
Deprotection of crude or purified peptide was investigated firstly using hydroboric acid in acetic acid 
containing pentamethylbenzene and thioanisole as scavengers. These reaction conditions were 
unsuccessfully applied to these peptides. A deprotection of Fmoc protected amino acid also showed 
only a small amount of deprotected amino acid. Further investigation on the deprotection of Fmoc 
protected amino acid using boiling triflouroacetic acid with anisole as a scavenger did not lead to the 
desired compound. Good turnover was seen applying tetrafluoroboric acid diethyl ether complex with 
thioanisole in trifluoroacetic acid. However, reinvestigating this method with synthesized modified 
peptides did not yield desired unprotected products. Due to successful inhibition studies of labelled 
alkyne modified µ-SIIIA no further investigations were made on the introduction of a seventh cysteine 
residue for labelling.  
3.3 Validation of folding pattern of µ-conotoxin SIIIA 
Due to the fact that recent studies on µ-SIIIA related µ-KIIIA presented by POPPE et al. and KHOO et al. 
suggested a different disulphide connectivity (1-5/2-4/3-6) compared to previously published data by 
KHOO et al. (1-4/2-5/3-6), the disulphide pattern of µ-SIIIA was validated in this thesis.[132,169,170] This 
validation is important to prove that the amount of different topological isomers formed is not caused 
by wrong disulphide connectivity. Reevaluation of disulphide bridged peptides such as µ-KIIIA is 
performed on the on hand, by an NMR based methodology, where disulphide connectivities are 
obtained by applying BAYESIAN rules of inference to the local topology of cysteine residues.[169] On the 
other hand, direct mass spectrometric collision-induced dissociation (CID) fragmentation is utilised, 
where the peptides are firstly digested by trypsin followed by a thorough mass analysis of formed 
tryptic peptides.[170] Previously, structures were derived by NMR spectroscopy including distance 
restraints on disulphide bridges based on an alignment with closely related µ-conotoxins, which was 
also done by YAO et al. for µ-SIIIA .[127] Even though SCHROEDER et al. probably included no distance 
restraints evaluating µ-SIIIA by NMR; the close relation of µ-SIIIA to µ-KIIIA suggests a similar disulphide 
connectivity. Comparison of the structure of µ-SIIIA (connectivity 1-4/2-5/3-6) by SCHROEDER et al. with 
the reevaluated structure of µ-KIIIA (connectivity 1-5/2-4/3-6) by KHOO et al. shows high similarity for 
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the α-helical motif and for important residues (see Figure 13); additionally, high inhibition rates are 
seen for both.[126,170] 
 
                    
Figure 13: Comparison of average ribbon structure of µ-SIIIA (left) (disulphide pattern 1-4/2-5/3-6) and µ-KIIIA 
(right) (disulphide pattern 1-5/2-4/3-6) showing the α-helical motif across residues 11-16. The three disulphide 
bonds are highlighted in yellow. The important residues for the affinity are highlighted in purple. See BMRB 
accession code 20025 and PDB code 2LXG, respectively.[126,170]  
 
Due to the uncertainty of structure of µ-SIIIA two peptides were synthesized by the previously 
described method with distinct disulphide pattern 1-4/2-5/3-6 (3) and 1-5/2-4/3-6 (27) (see Figure 14). 
Yields were comparable to previous syntheses and formation of different topological isomers was 
detected by HPLC (see Figure 15). Two main isomers were isolated for the 1-5/2-4/3-6 disulphide 
pattern and three for the 1-4/2-5/3-6 pattern. These results prove distinct isomer formation was not 
due to the modification of µ-SIIIA, but resulted from the disulphide formation using the regioselective 
approach. Comparison to commercially available µ-SIIIA, which should have the same retention time 
as native µ-SIIIA, did not lead to conclusions about disulphide pattern as one isomer of each pattern 
co-eluted with commercially available µ-SIIIA. Therefore, these two isomers were analysed by patch-
clamp experiments as described beforehand showing 65% of sodium current to be blocked for µ-SIIIA 
27 having 1-5/2-4/3-6 disulphide pattern and 80-100% for µ-SIIIA 3 having 1-4/2-5/3-6 pattern.    
 
 
Figure 14: Synthesized µ-SIIIA with 1-4/2-5/3-6 (3) and 1-5/2-4/3-6 (27) disulphide pattern. 
 





Figure 15: HPLC trace of µ-SIIIA with 1-4/2-5/3-6 (3) and 1-5/2-4/3-6 (27) disulphide pattern. Diverse set of 
topological isomers were formed. Isomers having same retention time on the HPLC as commercially available 
µ-SIIIA (highlighted with an arrow) were analysed by patch-clamp. 
 
These results supported previous assessments of disulphide bridges of µ-SIIIA indicating 1-4/2-5/3-6 
disulphide pattern to be the native conformation comparable to longer µ-conotoxins such as 
µ-conotoxin BuIIIB (disulphide connectivity determined through direct mass spectrometric CID 
fragmentation).[171]   
3.4 Synthesis of caged µ-conotoxin SIIIA 
In addition to the synthesis of labelled µ-SIIIA, a modified µ-SIIIA was synthesized bearing a 
photoremovable protecting group (PPG) on a residue important for binding to sodium channels. This 
caged molecule might be used for consecutive cell-attached patch-clamp experiments measuring the 
current before (no inhibition) and after (inhibition of NaV1.2) uncaging.  
3.4.1 Characteristics and applications of photolabile compounds 
Photoremovable protecting groups are utilised to temporarily block a number of functionalities e. g. 
acids, alcohols or amines.[172] Their characteristic feature is the spatially and temporally controlled 
cleavage upon photo-irradiation excluding the need for additional reagents which may interact with 
sensitive groups present in a molecule.[173] PPGs are commonly applied to explore diverse biological 
processes: biologically active molecules are rendered inactive by masking their functional groups with 
PPGs (leading to a caged compound) and subsequent photo-excitation results in an uncaging releasing 
the active compound with free functional groups.[174] KAPLAN et al. synthesized and analysed the first 
so called “caged molecule”: a phosphate PPG protected adenosine triphosphate (ATP) derivative.[175] 
Protected ATP does not act as a substrate of renal Na/K-ATPase, whereas after irradiation unprotected 
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has been extended to peptides and proteins. Photocaged amino acids are introduced either by SPPS 
or by genetically encoding using evolved aminoacyl-tRNA synthetase-tRNACUA pairs.[176] PPGs have 
already been broadly applied in the field of neural sciences and many photoactivable derivatives of 
neurotransmitters and neurotransmitter agonists are available. Thereby, precise analysis of the 
kinetics and mechanism of chemical synaptic transmission is possible. An example is the induction of 
whole cell current in HEK293 cells upon photolysis of nitrobenzyl N-protected glycine acting as a 
neurotransmitter in its uncaged form.[177]  
3.4.2 Photolabile nitrobenzyl protecting groups: mechanism and derivatives   
The photoremovable protecting groups mostly applied are based on the 2-nitrobenzyl PPG (NB). The 
mechanism of its cleavage has been widely studied using different spectroscopic tools.[178–183] Initially, 
photo-irradiation of 28 converts the nitro group into its excited state 29. Intramolecular hydrogen 
abstraction of the benzylic hydrogen by the excited nitro group then leads to the formation of the aci-
nitro intermediate 30, being resonance stabilized. Successive cyclization to 31 and ring opening results 
in the formation of hemiacetal 32 being hydrolysed to form the aldehyde or ketone 33 (depending on 
the residue) and releases the target molecule (TM) (see Scheme 13). A diverse range of target 
molecules can be used e. g. phosphates, carboxylates, carbonates, carbamates, thiolates and 
phenolates. Alcohols and amines are protected as a carbonate or carbamate; consecutive 
decarboxylation leads to liberated alkoxides or amines.[184] Substituents in the benzylic positions might 
be introduced to prevent reactions of formed aldehydes (R = H) with amines forming imines. An 
additional problem concerning the nitroso byproduct is its strong absorbance above 300 nm, which 
decreases the photoreaction efficiency.[179]  
 
 
Scheme 13: Photo-induced uncaging of the 2-nitrobenzyl protecting group. TM = target molecule.[184,185]  
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Various modifications of the aromatic ring are reported in literature, which are employed to improve 
the photochemical properties (quantum yield, cleavage efficiency and cleavage wavelength). The most 
frequently used NB analogues 6-nitroveratryl (also named 3,5-dimethoxy-o-nitrobenzyl = DMNB) and 
6-nitroveratryloxycarbonyl (NVOC) have two additional methoxy groups, which are added to shift the 
absorption maxima from 265 to 365 nm.[186] Under these conditions even the most light-sensitive 
amino acid, tryptophan, is not effected.[185] Due to the wide applicability of these groups they were 
used in this work.  
3.4.3 Structural analysis of µ-conotoxin SIIIA regarding the introduction of a 
caging group 
In the structural analysis of µ-SIIIA (see section 3.2.1 and 3.2.2) the important residues for binding, 
namely Lys11, Trp12, Arg14 and Arg18, were already described. The most frequently employed and 
easiest synthesizable caged amino acid out of this three is Fmoc-L-Lys(NVOC)-OH (34). Commonly used 
caged arginine is not incorporated into the peptide sequence by means of SPPS. Instead, an ornithine 
is integrated into the peptide sequence, which is guanylated by a special reagent, prepared from 
S-methylisothiourea and 6-nitroveratryl chloroformate, yielding an arginine after uncaging.[187] Owing 
to the fact that this guanylation reagent is reactive towards amines, it also reacts with unprotected 
lysine, and subsequently gives an arginine in this position after uncaging. Additionally, SCHROEDER et al. 
detected an enhanced affinity by substituting Asp15 with alanine, whereby the substitution of Asp15 
by either lysine (positive charge) or tyrosine (aromatic residue) strongly decreases the affinity towards 
NaV1.2.[126] These results suggest that only a small side chain is preferred in this position making it an 
optimal target for caging. Furthermore, the [His16Ala] substitution of µ-SIIIA drastically lowers the 
affinity to NaV1.2, which is probably due to structural changes. Therefore, histidine should not be 
caged, as a cage in this position might also influence the overall structure formation. Following this 
structural analysis two peptides were postulated for synthesis: one bearing a caged lysine and the 
other one bearing a caged aspartic acid (see Figure 16).  




Figure 16: Average ribbon structure of µ-conotoxin SIIIA showing the α-helical motif across residues 11-16. The 
three disulphide bonds are highlighted in yellow. The important residues for the affinity are highlighted in 
purple, the residues available for modification are shown in green, respectively. See BMRB accession code 
20025.[126]  
3.4.4  Synthesis of caged µ-conotoxin SIIIA 
For the synthesis of caged lysine, 4-nitrophenyl chloroformate (35) was reacted with 4,5-dimethoxy-2-
nitrobenzyl alcohol (36) to form an activated carbonate ester 37 as described by FOMINA et al.[188] In 
the following reaction with Fmoc protected lysine, previously described by DE GRACIA LUX et al., caged 
lysine 34 containing a carbamate function was obtained (see Scheme 14).[189] 
 
 
Scheme 14: Synthesis of Fmoc-L-Lys(NVOC)-OH (34). 
 
Synthesis of caged aspartic acid 38 was accomplished based on a procedure described by BOURGAULT 
et al. starting from Fmoc and tBu protected aspartic acid 39. [190] Instead of 
1,3-dicyclohexylcarbodiimide (DCC) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was used 
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as the carboxyl activating agent as separation of byproduct N,N’-dicyclohexylurea (DCU) was not 
possible either by precipitation or column chromatography. Byproducts of esterification with EDC were 
easily separated as these were water soluble.[191] Subsequent deprotection of the tBu protected 
carboxylic acid 40 by trifluoroacetic acid resulted in the caged aspartic acid 38 (see Scheme 15).   
 
 
Scheme 15: Synthesis of Fmoc-L-Asp(ODMNB)-OH (38). 
 
After preparation of the caged amino acids, they were integrated into the peptide sequence of µ-SIIIA 
as described earlier (see chapter 3.2.3). Test cleavage of linear peptide 41 containing caged lysine 
proved that the integration of this amino acid was successful. Formation of the 1st and 2nd disulphide 
bridge was accomplished in good yields (64% and 70% crude peptide 42 and 43, see Scheme 16). 
Purification of crude peptide 43 by HPLC was necessary after the formation of the 2nd disulphide bridge 
yielding one major product. As previously described, the 3rd disulphide bridge was synthesized using 
iodine but stirring was continued for 2 h due to the absence of a reactive alkyne moiety. Precipitation 
yielded the crude product 44, which was purified by HPLC. As the yield of the formation of the 3rd 
disulphide bridge was very poor (8%), another protecting strategy was investigated employing the 
enzyme labile cysteine protecting group Phacm instead of Acm (see chapter 3.1.2). Even though 
peptide synthesis and formation of the 1st and 2nd disulphide bridges were accomplished, the 3rd 
disulphide bridge was not formed by applying resin bound PGA as previously described by GÓNGORA-
BENÍTEZ et al.[77]  
 
Additionally, caged aspartic acid 38 was incorporated into the peptide sequence of µ-SIIIA. The peptide 
was synthesized as previously mentioned (see chapter 3.2.3). Mass analysis after a test cleavage of the 
resulting peptide did show a mass difference (m/z = -213), which corresponds to an aspartimide of 
uncaged peptide. Even though this was prevented for OtBu protected aspartic acid by applying HOBt 
into the deprotection solution, this reaction could not be prevented for the good leaving group 
ODMNB. However, BOURGAULT et al. observed problems with this protecting group for aspartic acid as 
well, directing the need for aspartimide suppressing conditions, which were used here.[190] As these 
conditions did not reduce aspartimide formation, future protection of aspartic acid should be 
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conducted using 3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl (DMNPB), which is stable during coupling/ 
deprotection conditions.[192,193]  
 
 
Scheme 16: Synthesis of [Lys11Lys(NVOC)]-µ-SIIIA (44). 
 
Initial uncaging experiments of µ-SIIIA 44 containing caged lysine were conducted in a mixture of 
acetonitrile/water by applying a 1000 W Hg(Xe) lamp as UV light source and irradiating at 650 W at 
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300-400 nm as previously described by PANSE.[160] Probes were taken after 1, 2 and 3 min and analysed 
by HPLC indicating a reduction of starting material but no product formation. Therefore, a milder light 
source, specifically a transilluminator for visualizing DNA bands in gels, was utilised, which was used 
beforehand by MÜLLER and PANSE for uncaging.[160,194] UV light with a wavelength of 365 nm was applied 
for 90 min. Every 15 min a probe was taken and analysed by LC-MS. Similar conditions were applied to 
uncage Fmoc-L-Lys(NVOC)-OH (34), which was completely deprotected after 30 min, and to native 
µ-SIIIA. For native µ-SIIIA, the formation of an additional peak at longer retention times was observed 
after 60 min (m/z = +2), which was probably due to the destruction of one disulphide bridge. Photolysis 
of disulphide bonds were already described by ZHOU et al. for a lower wavelength of 254 nm.[195] For 
caged µ-SIIIA first uncaging was observed after 30 min and after 75 min the starting material was 
consumed. Even though no product peak formation was detected by LC-MS at 215 nm after the 
uncaging process, the correct mass was seen at an earlier retention time compared to caged peptide. 
As these long cleavage times are incompatible with cell-attached measurements further investigations 
have to be made in the future. Possible side reactions such as destruction of disulphide bridges or 
imine side product formation might be prevented by changing the caging group. Furthermore, patch-
clamp experiments need to be conducted with caged µ-SIIIA 44 to investigate whether the introduction 
of a caged lysine impedes its binding affinity. Otherwise an option would be the introduction of several 
caged amino acids in one µ-SIIIA. Currently, investigations are carried out by JUNIUS synthesizing a caged 









4 Labelling of pompilidotoxin 
 
 
4.1 Characteristics and applications of pompilidotoxin 
Pompilidotoxins (Pmtxs) are toxins derived from the venoms of the spider wasps (Pompilidae) Anoplius 
samariensis (α-Pmtx) and Batozonellus maculifrons (β-Pmtx), which paralyse their prey instead of 
killing it, in order to feed their larvae with living prey.[40] After their first identification by KONNO et al., 
pompilidotoxins have been widely applied on different tissues to analyse their impact on ion 
channels.[196,197] SAHARA et al. discovered a slowing of the sodium channel inactivation process in TTX-
sensitive voltage-gated sodium channels (VGSCs) of rat trigeminal neurons by PMTX.[198] Further 
studies proved its selectivity to target rNaV1.2 over rNaV1.5 (rat sodium channels), showing its 
preference of neuronal over cardiac sodium channels.[199] Additionally, SCHIAVON et al. analysed its 
effect on eight different VGSC isoforms for their selective response to Pmtx.[40] NaV1.2 and NaV1.6 are 
the isoforms with the highest affinity, followed by NaV1.7 and NaV1.3. NaV1.4 and NaV1.5 does not 
induce any effect. The described absence of affinity for NaV1.4 and NaV1.5 is attributed to a Glu  Gln 
mutation between segment 3 and 4 of domain IV of the sodium channel, where the active binding site 
of Pmtx is incorporated.  
4.2 Structural analysis of pompilidotoxin 
α-Pmtx as well as β-Pmtx are composed of 13 amino acids, which differ only at position 12, where 
α-Pmtx has a lysine and β-Pmtx an arginine residue (see Figure 17). This small change induces a fivefold 
higher potency for β-Pmtx over α-Pmtx. Structure-activity relationships of synthetic analogues of 
α-Pmtx were conducted by SAHARA et al.[198] Deletion of the C-terminal amidation, or the first five or 
last four amino acids leads to a loss of activity. Furthermore, a [Ile2Phe] or [Phe7Tyr] replacement 
abolishes the activity. Additionally, 23 analogues were synthesized by KONNO et al. and compared to 
α- and β-Pmtx.[200] Substitution of basic amino acids of α-Pmtx such as lysine or arginine (forming 
mutants [Arg1Lys]-α-Pmtx or [Lys3Arg]-α-Pmtx) causes an increased activity comparable to that of 
β-Pmtx. However, double or triple mutants (based on α-Pmtx) do not have an increased potency 
compared to β-Pmtx. Modification of the position of the basic residues, such as a shift of lysine in 
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position 3 to position 4 or 5 leads to a loss of activity. Only the [Ser11Ala]-α-Pmtx mutant does not 





Figure 17: One letter code of α-Pmtx and β-Pmtx for comparison. The difference in position 12 is highlighted 
in green. The important residues for the affinity are highlighted in purple. The C-terminus is amidated 
(indicated by an asterisk). 
 
4.3 Synthesis of modified and labelled pompilidotoxin 
Following this detailed structural analysis, two alternatives were proposed in order to label 
β-pompilidotoxin (having higher activity than α-Pmtx): substitution of the serine at position 11 and 
elongation of the N-terminus, as there were no results on an elongation in this position. Introduction 
of a label in these positions might be accomplished either by a substitution with cysteine, which offers 
the opportunity to use a maleimide functionalized fluorophore, or with serine(2’-propyne), which can 
react with an azide functionalized fluorophore via CuAAC. Fmoc-L-Ser(2’-propyne)-OH (6) was 
synthesized according to the previously mentioned method (see Scheme 5). Syntheses of four peptides 
bearing either alkyne substituted serine or a cysteine in position 0 or 11 were performed on rink amide 
MBHA resin as solid support preloaded with Fmoc-L-Leu-OH according to Fmoc based SPPS protocols 
providing a C-terminal amide after cleavage (see Figure 18). In a first approach, aspartimide formation 
was reduced by adding 0.1 M 1-hydroxybenzotriazole (HOBt) to the deprotection solution, but 
standard coupling conditions (75 °C) were utilised.2 As aspartimide formation was still detected 
(m/z = -18), the temperature for all steps was reduced to 50 °C. Test cleavages of all protected peptides 
confirmed the formation of peptides 45-48.  
 
 
Figure 18: Synthesized alkyne or cysteine modified β-pompilidotoxins 45-48. 
                                                          
2 SPPS of 45 and 47 applying standard coupling conditions (75 °C) were carried out by SELDA KABATAS. 
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Alkyne modified peptide 45, resin loaded and fully protected, was subjected to copper(I)-catalysed 
azide-alkyne cycloaddition (CuAAC). Conversion with copper(I) iodide, sodium ascorbate as reducing 
agent and Alexa Flour® 488 azide, which was used in agreement with the SCHILD research group, was 
followed by cleavage and subsequent HPLC purification. Even though product was detected, it was 
obtained in a mixture with unreacted alkyne, which was not separable via HPLC. Therefore, the 
unlabelled alkyne modified peptides 45 and 47 were only submitted to patch-clamp analysis. The 
advantage of an alkyne moiety instead of a cysteine moiety for patch-clamp analysis was the avoidance 
of side effects, which might occur due to dimerization via disulphide bond formation in case of cysteine 
modified β-Pmtx. After deprotection of peptides 46 and 48, they were purified by HPLC. Subsequent 
conversion to labelled β-pompilidotoxins was achieved by reaction with Alexa Fluor® 488 C5 maleimide 
at a neutral pH (see Scheme 17). Tris(2-carboxyethyl)phosphine (TCEP) was utilised to reduce existing 
disulphide bridged compounds. Labelled peptides 49 and 50 were purified by HPLC in yields of 34% 
and 10%, respectively. Synthesized Alexa Fluor® 488 labelled β-pompilidotoxins were than analysed by 
GUOBIN BAO in the SCHILD research group to investigate sodium channels in olfactory receptor neurons 
(ORNs). 
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4.4 Analysis of modified and labelled pompilidotoxin 
Firstly, unlabelled alkyne modified peptide 45 was studied by patch-clamp experiments.3 Without toxin 
application sodium current was detected at depolarisation pulses of -30 mV and above. Even though 
the first sodium current for β-Pmtx was seen with a depolarisation pulse of -30 mV as well, the 
amplitude for -30 mV was increased compared to the control experiment, indicating an inhibition of 
sodium channel inactivation by β-Pmtx. Similar results were obtained by modified peptide 45, 
suggesting that the modified β-Pmtx was also able to inhibit or slow down sodium channel inactivation 
(see Figure 19).  
 
  A     B  
 
 
C     D 
    
Figure 19: Inhibition of sodium channels of ORNs by unmodified β-Pmtx and modified β-Pmtx 45. In the whole 
cell configuration patch-clamp recording was conducted with ORN cells, which were held at -70 mV and 
depolarized to -60 – 10 mV. Sodium currents were measured before (A and C) and after treatment with 
unmodified β-Pmtx (B) or modified β-Pmtx 45 (D). Application of 50 µM toxin induces a slowed inactivation. 
 
The effect of the toxins in terms of the additional current during depolarization with different voltages 
was further analysed with additional channel current/voltage (IV) curves before and after treatment. 
As shown in Figure 20 (left), after 45 treatment, sodium channel inactivation slows down, which 
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resulted in an additional current during the different depolarisation pulses. For 45, the additional 
sodium current was seen even at low depolarisation pulses (start at -50 mV) compared to natural 
β-Pmtx (see Figure 20 (right)), which showed the same effect after depolarisation pulses of -30 mV. A 
complete wash-out of 45 was detected after 3 min. However, 47 as well as related labelled 
pompilidotoxin 50 did not have any effect on the sodium current (see Figure 20 (right)). 
 
    
Figure 20: Sodium current/voltage curves for natural and modified β-Pmtx. Curves for modified β-Pmtx 45, 
after wash-out for 3 min and for modified β-Pmtx 47 are seen in the left diagram. A comparison of unmodified 
β-Pmtx and fluorophore labelled β-Pmtx 50 is shown in the right diagram.  
 
Initial fluorescence staining of ORN was conducted by GUOBIN BAO with fluorophore labelled β-Pmtx 49 
(see Figure 21). In the first image the autofluorescence of the cell is seen, in which two surface dead 
cells show a high autofluorescence. The second and third image shows the staining after three and ten 
minutes, respectively, whereas an accumulation of Alexa Fluor® 488 at the cell membrane was 
detected. A five minutes wash was performed as a control experiment, which removed staining by 
Alexa Fluor® 488. Therefore, only the autofluorescence was detected after wash-out.    
Figure 21: Staining sodium channels with 49 in ORN at a low concentration of 10 µM. Maximum intensity 
projection in Z is shown. Images were taken before and after staining for three and ten minutes. After washing 
for five minutes, only the autofluorescence was observed.
















































Before Staining 3 min  
Staining 10 min  Wash,5 min  
 
  





5 Labelling of iberiotoxin 
 
 
5.1 Characteristics and applications of iberiotoxin 
Since the first isolation of iberiotoxin (Ibtx) in 1990 from the venom of the scorpion Buthus tamulus by 
GALVEZ et al., it has become an interesting target for addressing calcium-activated potassium channels 
(BK channels).[201] Ibtx is composed of 37 amino acids containing three disulphide bridges. In 
comparison with charibdotoxin (Chtx), another scorpion-derived BK channel blocker having 68% 
sequence homology with Ibtx, Ibtx is more selective for BK channels. In contrast to Chtx, iberiotoxin 
distinguishes between BK channels and other voltage-gated ion channels, especially other potassium 
channels.[202] Ibtx binds to the external vestibule of the channel interacting with surface charges 
located there.[202]  
 
Owing to its high selectivity, several labels have been introduced to Ibtx. First labelling was performed 
by KNAUS et al. introducing a radiolabel utilising N-[3H]ethylmaleimide to react with recombinant 
[Asp19Cys]Ibtx.[203] In comparison, the double mutant [Asp19Tyr/Tyr36Phe]Ibtx, where tyrosine is 
specifically labelled with 125I, has improved radiolabel properties displaying high specific activity.[204] 
Therein, double mutation is necessary because direct labelling of Tyr36 reduces the binding affinity. 
This radiolabel method provides the tool to detect the coassembly of BK channels and L-type voltage-
gated calcium channels in rat brain.[205] The introduction of a fluorophore is accomplished on the one 
hand, by labelling free amines of Ibtx with rhodamine redTM succinimidyl ester to analyse Xenopus 
neurons in different embryonic stages.[36] On the other hand, recombinant [Asp19Cys]Ibtx is labelled 
with Alexa Fluor® 488 maleimide in order to directly visualize localisation of BK channels in mammalian 
cochlear hair cells.[206] The synthesis of a biotin derivative of Ibtx and its binding to Alexa Fluor® 488 
streptavidin conjugate was accomplished by BINGHAM et al. to image the surface distribution of BK 
channels on a transfected human cell line, revealing a patch-like surface distribution.[207] The 
positioning of labels on Ibtx was clearly dependent on the structural analysis of iberiotoxin, which will 
be discussed in the next section. 
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5.2 Structural analysis of iberiotoxin 
Structural analysis of Chtx as well as Ibtx reveals, that the 37 amino acids form a short triple-stranded 
β-sheet (residues 1-3, 26-29, 32-35), an α-helix (residues 10-19), and an extended fragment (residues 
5-7) (see Figure 22). These motifs are linked together by three disulphide bridges. A hydrophobic 
cluster is formed in the centre of the molecule by two groups of well-defined, low-accessible side 
chains (Thr3, Val5, Val16, Leu20, Cys33 and Leu2, His21, Thr23, Cys17 and Cys35) stabilizing the overall 
structure.[208] MILLER et al. provided further insights into the structure-activity relationship by point 
mutation of a number of amino acids for Chtx.[209,210] While mutation of certain charged residues has 
only small impact on the binding affinity (Lys11, Glu12, Arg19, His21, Lys31, Lys32), eight residues are 
highly important (Ser10, Trp14, Arg25, Lys27, Met29, Asn30, Arg34, Tyr36). These residues are located 
on the surface of the β-sheet. Even though, most point mutations induce a decrease in binding affinity, 
[Thr8Ser]Chtx has an increased binding affinity with twofold reduction in off-rate. However, 






Figure 22: Average ribbon structure of iberiotoxin related charybdotoxin (top): The three disulphide bonds are 
highlighted in yellow. The important residues for the affinity are highlighted in purple. See PDB code 2CRD.[208] 
One letter code of Chtx and Ibtx for comparison (bottom): Z = pGlu, the C-terminus is amidated (indicated by 
an asterisk). 
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Further differences between these two toxins are the presence of four additional negatively charged 
amino acids in iberiotoxin inducing a net charge of +1 (if Lys, Arg, Asp and Glu are ionised) in contrast 
to +5 of Chtx. These differences may be responsible for a fivefold lower on-rate compared to Chtx as 
the pore of the channel has a negative charge. The increase in off-rates must therefore be due to 
electrostatic asymmetry, Ibtx has a larger dipole moment because of the asymmetrical substitution of 
four additional aspartates, or specific interactions between residues.[211]  
5.3 Synthesis of labelled iberiotoxin 
As previously described (see section 5.1), many labelled iberiotoxins have already been researched. 
Even though solid phase peptide synthesis of Ibtx is possible and can be improved by applying NATIVE 
CHEMICAL LIGATION, most of the applied iberiotoxins are gained by recombinant expression.[212] 
Described labels are usually attached in the Arg19 position, as this residue is located in the α-helical 
motif, on the side of the molecule opposite to the binding site. Introducing a label in this position 
requires a change in amino acid backbone, usually a cysteine is introduced to have a target for 
maleimide reagents. A much simpler approach is the labelling of free amines of commercial available 
Ibtx with the fluorophore succinimidyl ester (see chapter 5.1). Even though Lys27 is highly important 
for the inhibition, specific labelling of ion channels is possible after labelling Ibtx with eight equivalents 
of rhodamine redTM succinimidyl ester.[36] Therefore, this method is applied in the SCHILD research 
group to label iberiotoxin. The amount of labels per Ibtx is estimated to be three to four labels per Ibtx 
(see section 2.3).[42] In this thesis, a tool for the exact quantification of BK channels was developed 
utilising commercially available recombinant Ibtx (51), missing cyclization at the N-terminus, which as 
stated by ALOMONE LABS does not have an influence on inhibition (see Scheme 18). Mono-labelling to 
52 was accomplished by utilising 0.7 eq. of Alexa Fluor® 546 carboxylic acid succinimidyl ester and was 
confirmed by mass analysis after HPLC purification. Further quantifications studies on BK channels 
forming clusters with VGCCs are yet to be made by BAO in the SCHILD research group. 




Scheme 18: Synthesis of mono-labelled Alexa Fluor® 546 iberiotoxin (52). The fluorophore was attached to one 














6.1 Role of cyclic adenosine-3’,5’-monophosphate in the chemotaxis of 
Dictyostelium discoideum 
Chemotaxis is defined as the directed migration of cells in chemical gradients.[213] It plays an important 
role in many eukaryotic processes, e. g. the healing process of wounds, which is facilitated by 
neutrophils (white blood cells) removing bacteria from the wound.[214] Furthermore, in cancer 
metastasis malignant cells move away from the tumour and towards blood vessels, directed by 
gradients of growth factors.[215] A widely applied model system for eukaryotic chemotaxis is the 
migration of the amoeboid Dictyostelium discoideum.[216] D. discoideum is an organism possessing a 
social cycle, where it is able to switch between proliferating as single amoeba and when starved 
aggregating into a cellular slime mould existing of approximately 105 cells.[217] This aggregation is driven 
by a spontaneous production and emission of cyclic adenosine-3’,5’-monophosphate (cAMP), which 
acts as a signal for neighbouring cells. Due to the fact, that D. discoideum cells are chemotactic towards 
cAMP, they come into close contact and aggregate.[218] Aggregation is followed by several 
morphological changes leading to the formation of a fruiting body, with stalk cells that carry spore 
cells, which survive unfavourable conditions. Following the release of the spore cells, they spread and 
the cycle is closed when they reach the amoeboid stage again.[219]  
 
The response of D. discoideum to cAMP is initiated by cAMP receptors (cAR), which are linked to a 
heterotrimeric G-protein.[216] A downstream signalling cascade eventually leads to a polarisation of the 
cell with an actin polymerisation in the front and a contracting acto-myosin network at the back of the 
cell.[220] For the quantification and visualization of cAMP concentration during experiments concerning 
the motility of D. discoideum, labelled cAMP is of great interest for researchers. Already, UEDA et al. 
utilised labelled cAMP to reveal the binding of individual cAMP receptors on the surface of living cells 
by single-molecule imaging techniques.[221] 
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6.2 Structural analysis of cyclic adenosine-3’,5’-monophosphate with 
regard to the binding to cAMP receptors of D. discoideum cells 
Binding studies of a number of cAMP derivatives to the surface of D. discoideum cells give a hint about 
the important functions involved in the interaction with cAR.[222–224] The binding affinity is strongly 
reduced when the cAMP derivative is no longer able to form hydrogen bonds at N6 or at 3’O (see Figure 
23). Though, substitution of N6H2 by chlorine has a stronger influence on affinity than a substitution 
with benzylamine, indicating that one hydrogen in this position is sufficient for hydrogen bond 
formation. Furthermore, the activation of the receptor requires a stereospecific interaction between 
cAR and the phosphate moiety of cAMP. Modifications at the 2’O- or 5’O-position, preventing 
hydrogen bonds in these positions, reduces the binding affinity only slightly.  
 
 
Figure 23: Structure of cyclic adenosine-3’,5’-monophosphate (53). Residues, important for binding to the 
cAMP receptor of D. discoideum cells, are indicated with an arrow. 
 
Resulting from these findings and synthetic considerations, two positions were proposed for labelling. 
On the one hand modification on N6, while preserving one hydrogen for the hydrogen bond, or on the 
other hand modification at the 2’O-position. 
6.3 Syntheses of labelled cyclic adenosine-3’,5’-monophosphates 
Labelling was performed utilising the bioorthogonal copper(I)-catalysed azide-alkyne cycloaddition 
(CuAAC). This will offer the possibility of further applications of functionalized cAMP, which will be 
discussed at the end of this chapter. For the synthesis of an N6-labelled cAMP a procedure described 
by KATAOKA et al., published in 1988, was followed.[225] Therein, a series of N6-alkyladenosine-3’,5’-cyclic 
phosphates are synthesized via a single step reductive alkylation starting from cAMP and the 
corresponding aldehydes. In this thesis, an aldehyde and an alkyne functionality were combined in one 
molecule, as this was needed for the CuAAC with an azide functionalized fluorophore. Therefore, 
commercially available 5-hexynol (54) was oxidized to 5-hexynal (55) by pyridinium chlorochromate 
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(PCC) as described by KOCSIS et al. (see Scheme 19).[226] Application of DESS-MARTIN periodinane instead 
of PCC did not increase the yield of the reaction. The small yield was probably a result of the low 
melting point of 55, leading to an evaporation during purification. For the following reaction with cAMP 
the tri-n-butylammonium salt of cAMP (56) was prepared according to the procedure of KATAOKA et al. 
to increase its solubility.[225] The product 57 of the following reductive amination was purified by HPLC 
utilising aqueous triethylammonium acetate solution as the solvent (see Scheme 19).  
 
 
Scheme 19: Syntheses of N6-hex-5-yn-1-yladenosine-3’,5’-cyclic monophosphate tri-n-butylammonium salt 
(57). 
 
The N6-alkyne functionalized cAMP 57 was labelled with Alexa Fluor® 488 azide, in agreement with our 
cooperation partner MARCO TARANTOLA. The reaction was performed based on a procedure by SEELA 
et al. performing CuAAC on functionalized nucleosides, and the manual for Alexa Fluor® 488 azide (see 
Scheme 20).[227] N6-Labelled cAMP 58 was purified by HPLC and verified by mass analysis.  




Scheme 20: Synthesis of N6-labelled cAMP 58. 
 
Chemotaxis assays, conducted with N6-labelled cAMP 58, did not show any directed migration of 
D. discoideum upon the application of 58.4 The bulky fluorophore in N6-position probably hindered the 
development of the hydrogen bond, which is necessary for the receptor binding. 
 
For the labelling of cAMP in 2’O-position, a synthetic pathway was considered, which included ester 
formation followed by an amide bond formation based on an approach by UEDA et al. (see Scheme 
21).[221] In the first step, cAMP (53) was reacted with succinic anhydride at a pH of 9.6 to form 59. The 
reaction was performed in both, water or aqueous sodium bicarbonate solution, while adjusting the 
pH with an aqueous sodium hydroxide solution. The reaction could not be conducted to completion 
and starting material 53 was not separable from the product by HPLC purification. In a subsequent 
conversion of the mixed products with 3-butyn-1-amine utilising 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC) as the carboxyl activating reagent, desired product 60 
was only found in traces during mass analysis. Consequentially, this synthetic pathway was no longer 
pursued.   
 
                                                          
4 All chemotaxis assays of Dictyostelium discoideum are based on gradient-mixer microfluidic devices and were 
performed under linear cAMP gradients by either NICK SCHOLAND or CHRISTOPH BLUM, both co-supervised by MARCO 
TARANTOLA and EBERHARD BODENSCHATZ. 




Scheme 21: Retrosynthetic analysis of 2’O-modified cAMP 60 based on a procedure of UEDA et al.[221] 
 
The 2’O-labelling of cAMP was therefore not based on esterification but on nucleophilic substitution, 
leading to a more flexible attachment of the linker. Additionally, this procedure has the advantage of 
being a one-step reaction. Published in 1990, KATAOKA et al. prepared 2’O-alkyl cAMP derivatives by 
reacting cAMP with alkyl bromides in the presence of potassium hydroxide and 18-crown-6 in a 
water/dioxane mixture.[228] The 2’O over N6-selectivity of the reaction can be seen by 1H-NMR and by 
determination of the absorption maximum, which is not changed in the case of the 2’O-derivative 
compared to unsubstituted cAMP. 
 
Firstly, the reaction was conducted utilising commercially available 4-bromo-1-butyne, which should 
give 2’O-modified cAMP 61. Because this reaction was unsuccessful, probably due to the neighbouring 
alkyne, and the introduction of a longer alkyne chain would be more comparable to the synthesized 
N6-modified cAMP 57, 6-bromo-1-hexyne was synthesized according to a procedure of SHARMA and 
OEHLSCHLAGER.[229] Subsequent reaction with cAMP (53) under the reaction conditions discussed above, 
yielded the 2’O-alkyne functionalized cAMP 62 in 50% (see Scheme 22). The product was purified by 
HPLC, leading to the tri-n-ethylammonium salt, and the product formation verified by NMR and mass 
analysis. The absorption maximum of 2’O-alkyne functionalized cAMP 62 was comparable to 
unmodified cAMP 53 (258 nm).  
 
 




Scheme 22: Synthesis of 2’O-hex-5-yn-1-yladenosine-3’,5’-cyclic monophosphate tri-n-ethylammonium salt 
(62). 
 
The subsequent copper(I)-catalysed azide-alkyne cycloaddition of 62 was performed similar to the 
previous CuAAC labelling N6-alkyne functionalized cAMP 57. HPLC purification yielded the desired 
2’O-labelled cAMP as the tri-n-ethylammonium salt 63 (see Scheme 23). In Figure 24, showing the 
corresponding HPLC traces, the good separability of the 2’O-alkyne functionalized cAMP 62 and the 
product 63 is shown. 
 
 
Scheme 23: Synthesis of 2’O-labelled cAMP 63. 
 




Figure 24: HPLC traces (intensity at 258 nm and 555 nm) of purified unlabelled (62) and labelled 2’O-alkyne 
functionalized cAMP (63). 
 
Chemotaxis assays by NICK SCHOLAND and CHRISTOPH BLUM, conducted with 2’O-labelled cAMP 63, did 
show directed migration of D. discoideum upon application of 63. The chemotactic index (CI), which is 
a measurement of the directness of a cell towards the chemoattractant, for 63 was comparable to the 
CI when applying unmodified cAMP. In Figure 25 the directed migration of D. discoideum cells towards 
the side with highest concentration of 2’O-labelled cAMP was visualized by showing the trajectories 
over time. The successful synthesis of 2’O-labelled cAMP clears the way to new applications. Recently, 
WESTENDORF et al. utilised a caged cAMP, which, upon irradiation with a laser beam, releases cAMP, to 
analyse chemotaxis of D. discoideum.[230] A combination of this approach with a modified labelling 
approach (where the label bears a caging unit as well), will offer the opportunity to have modified 
cAMP, that is activated by a laser beam and at the same time the fluorescence is released. 
 
Figure 25: Trajectories of D. discoideum over time, when 2’O-labelled cAMP 63 is applied. The distribution of 
63 is seen by the difference in background brightness (highest concentration in the upper-left corner).

































The development of new methods and tools for in vivo/in vitro labelling helps to elucidate structures, 
localisation and distinct processes of biomolecules in their native environment. Fluorescence labelling 
and detection provides researchers with a highly sensitive, non-destructive method to visualize 
biomolecules even on the nanometre scale. This thesis comprises two different approaches for 
fluorescent labelling. The first approach includes the indirect labelling of ion channels, in which ion 
channels are addressed by specific binding fluorescently labelled neurotoxins. The second project 
comprises a direct labelling approach, where a nucleotide is functionalized with a fluorophore for 
direct investigation of its concentration and localisation.  
 
Ion channels are membrane proteins, which are substantial for the signal translation and propagation 
in excitable cells by generating and shaping action potentials.[7] Although, the patch-clamp technique 
allows the monitoring of channel activity in localised regions of plasma membranes, limitations occur 
in the assignment of the distribution of ion channels in whole cell membranes of living cells.[30] 
Therefore, fluorescent labelling is applied by addressing ion channels with specifically binding 
neurotoxins, which, in comparison to most antibody labelling approaches, have high selectivity for the 
ion channel extracellular domains distinguishing between different ion channels and their subtypes.[31] 
The first neurotoxin labelled in this study was µ-conotoxin SIIIA, a disulphide rich peptide. The 
disulphide bridges were established by a consecutive approach. To validate the disulphide connectivity 
of native µ-conotoxin SIIIA, two isomers, discussed in literature, were synthesized (see Figure 
26).[127,170] Isomer 3 with a 1-4/2-5/3-6 disulphide pattern induced highest inhibition during patch-
clamp analysis by TING WANG.  
 




Four analogues of µ-conotoxin SIIIA were synthesized by the introduction of artificial H-L-Ser(2’-pro-
pyne)-OH in four different positions. Different topological isomers were isolated of each analogue and 
those modified in position Gly6 and Ser9 were already analysed by TING WANG on sodium channels 
determining two isomers with good binding affinities. In the key step, these were labelled via copper(I)-
catalysed azide-alkyne cycloaddition (CuAAC) with DIPEA as an additive (forming 20 and 21, see Figure 
27). For the Alexa Fluor® 647 labelled [Gly6Ser(2’-propyne)]-µ-SIIIA analogue 20 patch-clamp 
experiments were conducted, proving its strong remaining activity after labelling. In the near future, 
further analysis of its labelling properties will be followed by imaging experiments. In addition to the 
synthesis of labelled µ-conotoxin SIIIA a caged compound was presented, bearing the photocleavable 
protection group 6-nitroveratryloxycarbonyl (NVOC) on the ε-amine of lysine (see Figure 27, 44). 
Uncaging was accomplished only after illumination for a long time with a mild light source. 
Supplementary studies of the uncaging process and patch-clamp experiments of caged compound will 
reveal its potency as a light-sensitive inhibitory switch for sodium channels. Additionally, the caging 
group may be changed from an aldehyde to a ketone releasing, thereby avoiding the imine formation 
by the reaction of free aldehydes of the caging group (upon uncaging) with free amine groups present 
in µ-conotoxin SIIIA. Furthermore, multiple caging groups may be incorporated to facilitate a greater 
reduction of activity before uncaging.    
 
 
Figure 27: Synthesized labelled analogues of µ-conotoxins SIIIA modified in position Gly6 (20) and Ser9 (21) 




The functionalization of two other neurotoxins, β-pompilidotoxin and iberiotoxin, with fluorescent 
labels was successfully developed. While β-pompilidotoxin slows the inactivation of voltage-gated 
sodium channels, iberiotoxin blocks calcium-activated potassium channels.[40,41] Structural analysis led 
to the successful labelling of linear β-pompilidotoxin on the N-terminus and at position Ser11, since a 
[Ser11Ala] modification has no influence on the overall activity (see Figure 28, 49 and 50). 
Bioorthogonal linkage was accomplished by the use of the cysteine/maleimide reaction. Patch-clamp 
experiments with unlabelled 49 and imaging experiments with labelled 49 conducted by GUOBIN BAO 
of the SCHILD research group indicated this compound to be a good tool for labelling sodium channels. 
The task of labelling iberiotoxin was approached by the amine/succinimidyl ester reaction. To avoid 
consecutive disulphide bridge formation, commercially available iberiotoxin was labelled directly. 
Mono-labelling was successfully achieved by applying an excess of iberiotoxin in the reaction (see 
Figure 28, 52). Subsequent co-localisation and quantification studies with voltage-gated calcium 
channels in olfactory receptor neurons will be conducted in the near future. 
 
 
Figure 28: Structural conformation of novel Alexa Fluor® 488 labelled pompilidotoxins (49, 50) and Alexa Fluor® 
546 labelled iberiotoxin (52). 
 
A further approach was the labelling of cyclic adenosine-3’,5’-monophosphate (cAMP), which acts as 
a chemoattractant for the amoeboid Dictyostelium discoideum, to investigate cAMP concentration 
dependent migration of these amoeboids. CuAAC was utilised for the linkage of fluorescent probes in 
the N6- and 2’O-position (forming 58 and 63, Figure 29), offering, with the alkyne modified cAMP, a 
tool for further applications. The 2’O-labelled cAMP 63 was successfully employed for migration 
studies of D. discoideum, while N6-labelled cAMP 58 did not induce migration. In the future, a 
combination of this labelling approach and the caging approach described by WESTENDORF et al. might 




suppressing its binding to the cAMP receptor and additionally, a caging moiety will be introduced to 
the fluorophore, quenching its fluorescence. Upon uncaging, this would lead to a fluorescent cAMP, 
which regains its activity to induce migration of amoeboids. 
 
 














Technical solvents were purified by distillation prior to use. Solvents of analytical or HPLC grade were 
used as supplied from FLUKA, FISHERSCIENTIFIC GMBH, SIGMA ALDRICH, VWR INTERNATIONAL, ROTH and ACROS 
ORGANICS. Dry solvents were stored over molecular sieves (4 Å). Ultra-pure water was obtained by 
purifying distilled water with the purification device SIMPLICITY (MILLIPORE). 
 
Reagents 
All reagents were of highest grade available and used as supplied. Amino acids and amino acid 
derivatives as well as resins, linker and coupling reagents for solid phase synthesis were obtained from 
NOVABIOCHEM, IRIS BIOTECH, GL BIOCHEM, BACHEM, MERCK, VWR INTERNATIONAL, ROTH and SIGMA ALDRICH. All 
other chemicals were purchased from FISHER SCIENTIFIC GMBH, ALOMONE LABS, SPRIN-TECHNOLOGIES, ALFA 




Air and/or water sensitive reactions were carried out under argon atmosphere using standard SCHLENK-
technique. The glass apparatus was heated with a heat gun under reduced pressure and flushed with 
argon (3 x).  
 
Freeze-drying 
Lyophilisation from aqueous solutions and aqueous mixtures containing minor amounts of acetonitrile 
or tert-butanol was performed using a CHRIST Alpha-2-4 lyophiliser equipped with a high vacuum pump. 






Thin layer chromatography (TLC) 
Analytical TLC was performed on MERCK silica gel 60 F254 (layer thickness 0.25 mm) aluminium backed 
plates. The plates were visualized under UV fluorescence (254 nm) or developed using ninhydrin 
(0.30 g ninhydrin, 100 mL EtOH) and charring to detect amines. 
 
Column chromatography 
Flash column chromatography was carried out using MERCK silica gel 60 (40-63 µm) at 0.4-1.0 bar. 
Columns were packed with wet silica gel (50-100 fold weight excess) and the sample loaded onto silica 
or loaded as a concentrated solution. 
 
High performance liquid chromatography (HPLC) 
Reverse Phase (RP)-HPLC analyses were performed using a system from JASCO equipped with two 
pumps PU-2080Plus, a multi wavelength detector MD-2010Plus either with an analytical or preparative 
cell, a 3-line degasser DG-2080-53 and interface LC-Net II/ADC. Substances were analysed or purified 
with a linear gradient of A (water or triethylammonium acetate (TEAA) buffer) to B (solvent containing 
mainly MeCN) using the following columns: 
 Analytical: MN Nucleodur® 100-5-C18, 250 mm x 4.6 mm, 5 µm, flow rate: 1 mL/min. 
 Semipreparative: MN Nucleodur® 100-5-C18, 250 mm x 10 mm, 5 µm, flow rate: 3 mL/min. 
 Preparative: MN Nucleodur® 100-5-C18, 250 mm x 21.0 mm, 5 µm, flow rate: 10 mL/min. 
 
Liquid chromatography-mass spectrometry (LC-MS) 
For LC-MS analyses the mass spectrometer from FINNIGAN (LCQ), the detector from FINNIGAN (Surveyor 
PDA), pumps from FLUX INSTRUMENTS (rheos 400), the degasser from KONTRON (degasser 3492) and the 
auto-sampler from JASCO (AS-1555) were used. A C-18 column (MN Nucleodur® 100 mm x 2 mm, S-
3 µm, 11 nm, flow 0.3 mL/min) was utilised using a linear gradient of A (99.95% water + 0.05% formic 
acid) to B (99.95% MeOH + 0.05% formic acid).  
 
Solid phase peptide synthesis (SPPS) 
Manual SPPS was conducted on solid support using PE-frit equipped BD discardit syringes as reaction 
vessel and the “Discover” microwave (CEM). Peptides were automatically synthesized using the 







Nuclear magnetic resonance spectroscopy (NMR) 
NMR spectra were recorded on a VARIAN spectrometer (Unity 300, Mercury 300, Mercury-Vx 300, 
VNMRS-300, Inova 500, and Inova 600). The sample temperature was 298 K except stated otherwise. 
The chemical shift are quoted in ppm downfield on a δ-scale. As internal standards the resonances of 
the residual protons of the deuterated solvents were used.[231] The abbreviations for the multiplets 
are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Coupling constants are 
nJX,Y in Hertz (Hz) where n is the order of coupling and X and Y the coupling partners. 13C-spectra and 
31P-spectra were measured as 1H-broadband decoupled or as APT-spectra (13C only). 
 
Mass spectrometry 
Electrospray-ionisation (ESI) and high resolution ESI (HR-MS (ESI)) spectra were obtained with BRUKER 
devices (maXis or MicrOTOF). Matrix assisted laser desorption/ionisation (MALDI) spectra were 
obtained with BRUKER devices (MALDI-TOF) using 2,5-dihydroxybenzoic acid as the matrix. 
 
UV/Vis spectroscopy 
UV spectra for estimation of occupancy were measured using the JASCO UV/Vis spectrophotometer 
V550. Peptide concentrations were estimated using a THERMO SCIENTIFIC nanodrop ND-2000c 
spectrophotometer and calculated by using LAMBERT-BEER’s law (for extinction coefficients see Table 
3). The molecular absorption coefficients were calculated by summation of the single coefficients at a 
set wavelength. For fluorescently labelled molecules the absorption was measured for the maximum 
absorption of the labels.  
 
Table 3: Extinction coefficients for tryptophan (Trp) and disulphide bonds (average values in folded proteins), 
caged lysine and of Alexa Fluor® dyes.[232–234] 




Trp 280 5500 
S-S 280 125 
Caged lysine 350 5485 
Alexa Fluor® 488 495 73000 
Alexa Fluor® 546 556 112000 
Alexa Fluor® 555 555 155000 





8.3 Standard operating procedures (SOPs) 
8.3.1 SOP1: Preloading resin with linker 
2-Chlorotrityl chloride resin (385 mg, 0.58 mmol, 100-200 mesh, 1.50 mmol/g) was swollen in a BD 
discardit syringe with PE frit in dry DCM (6 mL) for 2 h. RAMAGE-linker (176 mg, 348 µmol, 0.60 eq.) and 
DIPEA (237 µL, 1.39 mmol, 2.40 eq.) were dissolved in dry DCM (4 mL), a small amount of dry DMF was 
added to dissolute the acid. This solution was added to the resin and the mixture shaken for 30 min. 
The resin was washed with DCM/MeOH/DIPEA (17:2:1, v/v/v, 3 x 6 mL), DCM (3 x 6 mL), DMF (2 x 6 mL), 
DCM (2 x 6 mL) and dried under reduced pressure. 
8.3.2 SOP2: Loading resin with first amino acid 
Either 2-chlorotrityl chloride or rink amide MBHA resin were used in this work. Loading of the resins is 
described here exemplarily for the rink amide MBHA resin. The rink amide MBHA resin (345 mg, 
0.10 mmol, 1.00 eq., 0.29 mmol/g) was swollen in DCM (6 mL) for 2 h. The Fmoc-protecting group was 
cleaved microwave assisted (30 s, 50 °C, 25 W) by 20% piperidine in NMP (4 mL). The resin was washed 
with NMP (5 mL) and the second cleavage (20% piperidine in NMP) was performed using a microwave 
(3 min, 50 °C, 25 W). After washing with NMP (3 x 5 mL), DCM (5 x 5 mL) and NMP (5 x 5 mL) coupling 
of the first amino acid cysteine was performed using Fmoc-L-Cys(Trt)-OH (293 mg, 0.50 mmol, 
5.00 eq.), DIC (76.0 µL, 4.90 mmol, 4.90 eq.), HOBt (66.2 mg, 4.90 mmol, 4.90 eq.) in NMP (3 mL) for 
10 min at 40 °C and 20 W. Final washing was performed using NMP (3 x 5 mL), DCM (5 x 5 mL), NMP 
(5 x 5 mL) and DCM (3 x 5 mL) and the resin was dried under reduced pressure. 
8.3.3 SOP3: Determination of the occupancy 
The resin load was estimated using UV absorption measurements. To a small amount of resin 
(approximately 5 µmol with respect to Fmoc) in a graduated flask (10 mL) 2% DBU in DMF (2 mL) were 
added. After agitating for 30 min the solution was diluted (to 10 mL) with MeCN. Another dilution with 
acetonitrile (1/12.5) was applied before UV absorption was recorded in a 1 cm cuvette. The absorption 
was measured at 304 nm, as reference solution everything was performed without addition of the 








8.3.4 SOP4: Automated SPPS 
Peptides were synthesized by standard Fmoc/tBu peptide synthesis on solid support. Side chain 




trityl for Asn, Gln and His; 2,2,4,6,7-pentamethyldihydrofurane-5-sulphonyl (Pbf) for Arg and trityl, 
StBu, acetylaminomethyl (Acm), dimethoxytrityl (Dmt), 4-methylbenzyl (Mbzl) and 
phenylacetylaminomethyl (Phacm) for Cys. NMP was used as the solvent. The resin (0.10 mmol) was 
swollen in DMF (4 mL) for 2 h prior usage. Deprotection was performed using piperidine (20% in NMP 
+ 0.10 M HOBt, 2 x 2.5 mL, 3 min, 50 °C, 20 W  3 min, 50 °C, 35 W). Fmoc protected amino acids were 
used as a 0.20 M solution in NMP except for Fmoc-L-Cys(Dmt)-OH, Fmoc-L-Cys(StBu)-OH, 
Fmoc-L-Cys(Acm)-OH, H-L-pGlu-OH, Fmoc-L-Ser(2’-propyne)-OH, Fmoc-L-Lys(NVOC)-OH and 
Fmoc-L-Asp(ODMNB)-OH, which were dissolved in DMF. Double coupling was conducted microwave-
assisted (all amino acids: 10 min, 40 °C, 20 W; Arg: 25 min, rt, 0 W  10 min, 40 °C, 20 W; His: 1 h, rt, 
0 W) using activation with HBTU/HOBt (0.5 M/0.45 M in DMF) and DIPEA (2.00 M in NMP). After the 
synthesis was completed the resin was transferred into a BD discardit syringe with PE frit, washed with 
NMP (3 x 6 mL), DCM (3 x 6 mL), DMF (3 x 6 mL) and DCM (3 x 6 mL) and dried under reduced pressure.  
8.3.5 SOP5: Manual SPPS 
The peptides were synthesized using the same protection groups as for the automated SPPS. The 
preloaded resin (0.10 mmol) was swollen in NMP (6 mL) for 2 h. The Fmoc-protecting group was 
cleaved microwave assisted (30 s, 50 °C, 25 W) by 20% piperidine, 0.10 M HOBt in DMF (4 mL). The 
resin was washed with NMP (5 mL) and the second cleavage (20% piperidine, 0.10 M HOBt in DMF, 
4 mL) was performed on a microwave (3 min, 50 °C, 25 W). After washing with NMP (3 x 5 mL), DCM 
(5 x 5 mL) and NMP (5 x 5 mL) coupling of the first amino acid was performed using a solution of the 
amino acid in NMP (0.20 M, 2.50 mL), HBTU/HOBt (0.50 M/0.45 M in DMF, 1 mL) and DIPEA (2.00 M in 
NMP, 0.50 mL) for 10 min at 40 °C and 20 W. After washing with NMP (3 x 5 mL), DCM (5 x 5 mL) and 
NMP (5 x 5 mL) the coupling was repeated followed by the next Fmoc-deprotection. Final washing was 
performed using NMP (3 x 5 mL), DCM (5 x 5 mL), NMP (5 x 5 mL) and DCM (3 x 5 mL) and the resin 
was dried under reduced pressure. 
 
8.3.6 SOP6: Cleavage 
Cleavage from resin and simultaneous removal of most side chains (depending on the protecting 
strategy) was performed using A (reagent K (TFA/H2O/1,2-ethanedithiol/phenol/thioanisole 
82.5:5:2.5:5:5 v/v/v/v, 10 mL/g resin) or B (TFA/H2O/TIS 95:2.5:2.5, v/v/v, 10 mL/g resin) and shaking 
for 2 h. After cleavage the solution was concentrated under nitrogen stream. The crude peptide was 
precipitated from -20 °C cold diethyl ether, isolated by centrifugation (9000 rpm, 2.5 min, -10 °C), 





8.3.7 SOP7: Synthesis of µ-conotoxin SIIIA: formation of the first disulphide 
bridge and deprotection of acid-labile protecting groups 
The resin was swollen in DMF (6 mL) for 2 h. Then following steps were performed (exemplarily shown 
for 6 mL in steps 1-4, 205 mL in step 4 and 100 mL in step 5): 
1. The StBu-protecting group of cysteine was cleaved using 20% 2-mercaptoethanol and 1% DBU 
in DMF (6 mL, 3 x 2 mL, 20 min each) followed by washing with DMF (3 x 6 mL), DCM (2 x 6 mL), 
DMF (2 x 6 mL) and DCM (3 x 6 mL). 
2. The free thiol was activated using 2,2’dipyridyl disulphide (135 mg, 0.61 mmol) in DCM (6 mL) 
(6 mL, 3 x 2 mL, 20 min each) followed by washing with DCM (3 x 6 mL), DMF (3 x 6 mL) and 
DCM (3 x 6 mL). 
3. Cleavage from the resin was performed using 10% AcOH and 20% TFE in DCM (6 mL, 3 x 2 mL, 
20 min each). 
4. Under argon atmosphere this solution (6 mL) was added dropwise to a solution of 0.1% TFA 
(205 µL) and 0.2% TES (410 µL) in DCM (204 mL). The reaction mixture was stirred overnight 
at rt. 
5. Under argon atmosphere this solution was added dropwise over 1 h to a solution of 10% NEt3 
(10 mL) in DCM (90 mL). The solution was concentrated to 10 mL under reduced pressure. The 
peptide was precipitated from -20 °C cold diethyl ether (50 mL), isolated by centrifugation 
(9000 rpm, 10 min, -10 °C), washed three times with cold diethyl ether followed by 
centrifugation and dried overnight under reduced pressure.  
6. Deprotection of acid-labile protecting groups was performed for 2 h using TFA/H2O/TIS 
(95:2.5:2.5, v/v/v) (6 mL). The solution was concentrated under nitrogen stream. The crude 
peptide was precipitated from -20 °C cold diethyl ether, isolated by centrifugation (9000 rpm, 
10 min, -10 °C), washed three times with cold diethyl ether followed by centrifugation and 
dried overnight under reduced pressure to yield a colourless solid. 
 
8.3.8 SOP8: Synthesis of µ-conotoxin SIIIA: formation of the second disulphide 
bridge 
Based on a procedure of TAM et al., crude peptide (23.4 µmol) was added to a solution of 5% acetic 
acid (2.50 mL) in water (47.5 mL) (pH was adjusted with (NH4)2CO3 to pH 6).[156] DMSO (12.5 mL) was 
added and the solution was stirred for 4 h at rt, the solvent was removed under reduced pressure and 
co-evaporated with DMF. The crude peptide was dissolved in a small amount of TFA and precipitated 




with -20 °C cold diethyl ether followed by centrifugation and dried overnight under reduced pressure 











According to the procedure of CORTEKAR, NaH (921 mg, 23.0 mmol, 2.70 eq., 60% dispersion in mineral 
oil) was suspended in dry DMF (7 mL) under argon atmosphere and cooled to 0 °C, followed by addition 
of Boc-L-Ser-OH (4) (1.75 g, 8.54 mmol, 1.00 eq.) dissolved in DMF (28 mL).[141] After 10 min 
propargylbromide (1.58 g, 10.7 mmol, 1.25 eq., 80% in toluene) was added dropwise to the mixture 
and the reaction stirred for 4 h at rt. The reaction was quenched with water and evaporated under 
reduced pressure. The resulting residue was dissolved in water (70 mL) and the reaction mixture 
adjusted to pH = 3 with 12 M HCl, extracted with EtOAc (3 x 50 mL), dried over MgSO4 and evaporated 
under reduced pressure. The crude product was purified by flash column chromatography 
(EtOAc/MeOH/AcOH 8.5:1.5:0.1, v/v/v) to yield the product 5 as a yellow oil (2.07 g, 8.52 mmol, 99%). 
The NMR data is in accordance to the literature.[236] 
 
TLC (EtOAc/MeOH/AcOH 8.5:1.5:0.1, v/v/v): Rf = 0.68. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.42 (s, 9H, C(CH3)3), 2.45 (t, 4JH,H = 2.4 Hz, 1H, CCH), 3.78-4.01 
(m, 2H, β-CH2), 4.12-4.19 (m, 2H, OCH2), 4.43-4.45 (m, 1H, α-CH), 5.46 (d, 3JH,H = 8.2 Hz, 1H, NH), 11.03 
(s, 1H, COOH). 
13C-NMR (126 MHz, CDCl3): δC (ppm) = 28.2 (C(CH3)3), 53.6 (α-CH), 58.6 (OCH2), 69.5 (β-CH2), 75.2 (CCH), 
78.8 (CH2CCH), 80.2 (C(CH3)3), 155.6 (Fmoc-CO), 174.2 (CO2H). 
HR-MS (ESI): calc. for [C11H17NNaO5]+ ([M+Na]+): 266.0999, found: 266.1001; calc. for [C11H16NO5]- 









According to the procedure of CORTEKAR, TFA (16 mL) was added to Boc-L-Ser(2’-propyne)-OH (5) 
(2.07 g, 8.52 mmol, 1.00 eq.) at 0 °C, stirred for 30 min and evaporated under reduced pressure.[141] 
The resulting residue was dissolved in 10% Na2CO3 (aq) (23 mL) at 0 °C. 9-Fluorenylmethoxycarbonyl 
chloride (2.43 g, 9.39 mmol, 1.10 eq.) dissolved in dioxane (20 mL) was added to the solution and the 
mixture stirred for 1 h at 0 °C, 1 h at rt and quenched with water (21 mL). The reaction mixture was 
washed with diethyl ether (2 x 40 mL), the aqueous phase was adjusted to pH = 1 with 12 M HCl, 
extracted with EtOAc (2 x 60 mL) and the combined organic phases were evaporated under reduced 
pressure. The crude product was purified by flash column chromatography (pentane/EtOAc/AcOH 
6:4:0.1, v/v/v) to yield the product 6 as a colourless solid (2.08 g, 5.70 mmol, 67%). The NMR data is in 
accordance to the literature.[141] 
 
TLC (Pentane/EtOAc/AcOH 6:4:0.1, v/v/v): Rf = 0.20. 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 3.43 (t, 4JH,H = 2.4 Hz, 1H, CCH), 3.72 (d, 3JH,H = 5.4 Hz, 2H, 
β-CH2), 4.16 (d, 4JH,H = 2.4 Hz, 2H, OCH2), 4.19-4.30 (m, 4H, α-CH, Fmoc-CH2, Fmoc-CH), 7.33 (dt, 
3,4JH,H = 7.4, 1.3 Hz, 2H, Fmoc-CH), 7.42 (dt, 3,4JH,H = 7.5, 1.2 Hz, 2H, Fmoc-CH), 7.59 (d, 3JH,H = 8.2 Hz, 1H, 
NH), 7.74 (d, 3JH,H = 7.4 Hz, 2H, Fmoc-CH), 7.89 (d, 3JH,H = 7.5 Hz, 2H, Fmoc-CH), 12.72 (s, 1H, CO2H). 
13C-NMR (126 MHz, CDCl3): δC (ppm) = 46.6 (Fmoc-CH), 53.9 (α-CH), 57.6 (OCH2), 65.7 (Fmoc-CH2), 68.6 
(β-CH2), 77.3 (CCH), 79.8 (CCH), 119.9, 125.1, 126.9, 127.4 (Fmoc-CH), 140.5, 143.6 (Fmoc-C), 155.8 
(Fmoc-CO), 171.1 (CO2H). 
HR-MS (ESI): calc. for [C21H19NNaO5]+ ([M+Na]+): 388.1155, found: 388.1150; calc. for [C21H18NO5]- 








According to the procedure of LINDNER, H-L-Cys-OHH2OHCl (1.00 g, 5.69 mmol, 1.00 eq.) was co-
evaporated with pyridine (3 x 4 mL) and dissolved in pyridine (4 mL) under argon atmosphere.[81] After 
addition of 4,4’-dimethoxytrityl chloride (1.83 g, 5.41 mmol, 0.95 eq.) the reaction mixture was stirred 
for 48 h at 50 °C and the reaction process monitored by TLC (DCM/MeOH 10:0.2, v/v). The solvent was 
evaporated under reduced pressure. The resulting residue was suspended in 20% Na2CO3 (aq) 
(12.5 mmol, 6.63 mL, 2.20 eq.) at 0 °C. (9-Fluorenylmethoxycarbonyloxy)succinimide (1.73 g, 
5.12 mmol, 0.90 eq.) dissolved in dioxane (6 mL) was added to the solution and the mixture stirred for 
15 min at 0 °C, followed by 4 h at rt. The mixture was adjusted to pH = 5 with citric acid, extracted with 
EtOAc (3 x 10 mL) and the combined organic phases were evaporated under reduced pressure. The 
crude product was purified by flash column chromatography (DCM/MeOH 10:0.2  10:0.5, v/v) to 
yield the product 11 as a yellow solid (2.20 g, 3.41 mmol, 60%). 
 
TLC (DCM/MeOH 10:0.5, v/v/v): Rf = 0.33. 
1H-NMR (600 MHz, [D6]DMSO): δ (ppm) = 2.48-2.56 (m, 2H, β-CH2), 3.71 (s, 6H, OCH3), 3.88-3.91 (m, 
1H, α-CH), 4.21-4.28 (m, 3H, Fmoc-CH, Fmoc-CH2), 6.85 (d, 3JH,H = 8.5 Hz, 4H, Dmt-CH), 7.18 (d, 
3JH,H = 8.5 Hz, 4H, Dmt-CH), 7.19-7.31 (m, 8H, Dmt-CH, Fmoc-CH, NH), 7.38-7.41 (m, 2H, Fmoc-CH), 7.73 
(d, 3JH,H = 7.5 Hz, 2H, Fmoc-CH), 7.88 (d, 3JH,H = 7.5 Hz, 2H, Fmoc-CH).   
13C-NMR (126 MHz, CDCl3): δC (ppm) = 34.1 (β-CH2), 46.6 (Fmoc-CH), 54.1 (α-CH), 55.0 (OCH2), 65.6 
(Fmoc-CH2), 113.1 (Dmt-CH), 120.0, 125.2 (Fmoc-CH), 126.4 (Dmt-CH), 127.0, 127.5 (Fmoc-CH), 127.8, 
128.9, 130.2 (Dmt-CH), 136.7 (Dmt-C), 140.6, 143.7 (Fmoc-C), 145.2 (Dmt-C), 155.5 (Fmoc-CO), 157.6 
(Dmt-C), 172.6 (CO2H). 
HR-MS (ESI): calc. for [C39H39N2O6S]+ ([M+NH4]+): 663.2523, found: 663.2500; calc. for [C39H34NO6S]- 








According to the procedure of FOMINA et al., 4,5-dimethoxy-2-nitrobenzyl alcohol (36) (2.50 g, 
11.7 mmol, 1.00 eq.) and 4-nitrophenyl chloroformate (35) (PNPCl) (4.70 g, 23.5 mmol, 2.00 eq.) were 
dissolved in DCM (25 mL) under argon atmosphere and exclusion of light.[188] DIPEA (4.18 mL, 
23.5 mmol, 2.00 eq.) and DCM (25 mL) were added and the solution stirred overnight at rt. The solvent 
was removed under reduced pressure, the resulting residue washed with hot EtOH (3 x 20 mL) and 
dried under reduced pressure to yield the product 37 as a yellow solid (2.56 g, 6.77 mmol, 58%). The 
NMR data is in accordance to the literature.[188,237] 
  
1H-NMR (300 MHz, CDCl3): δ (ppm) = 3.99 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 5.71 (s, 2H, CH2), 7.11 (s, 
1H, DMNB-H6), 7.41 (d, 3JH,H = 9.2 Hz, 2H, PNP-H2,H6), 7.77 (s, 1H, DMNB-H3), 8.30 (d, 3JH,H = 9.2 Hz, 
2H, PNP-H3,H5). 
13C-NMR (126 MHz, CDCl3): δC (ppm) = 56.6 (OCH3), 56.7 (OCH3), 67.9 (CH2), 108.6 (DMNB-C3), 110.8 
(DMNB-C6), 121.9 (PNP-C2,C6), 125.2 (DMNB-C1), 125.5 (PNP-C3,C5), 140.2 (DMNB-C2), 145.7 
(PNP-C1), 149.0 (DMNB-C5), 152.2 (CO), 153.8 (DMNB-C4), 155.5 (PNP-C4). 








According to the procedure of DE GRACIA LUX et al., Fmoc-L-Lys-OH (2.50 g, 6.79 mmol, 1.00 eq.) was 
dissolved in toluene (122 mL) and added to a suspension of 4,5-dimethoxy-
2-nitrobenzyl(4-nitrophenyl)carbonate (37) (2.56 g, 6.79 mmol, 1.00 eq.) and DIPEA (24.4 mL) in DMF 
(41 mL) under argon atmosphere and exclusion of light.[189] The reaction mixture was stirred overnight 
at rt and the solvent removed under reduced pressure. The resulting yellow oil was purified by flash 
column chromatography (DCM/MeOH/AcOH 10:0.5:0.1  10:1:0.1, v/v/v) to yield the product 34 as 
a slightly yellow solid (2.64 g, 4.34 mmol, 64%). The NMR data is in accordance to the literature.[189] 
 
TLC (DCM/MeOH/AcOH 10:0.5:0.1, v/v/v): Rf = 0.19. 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 1.26-1.49 (m, 4H, δ-CH2, γ-CH2), 1.59-1.72 (m, 2H, β-CH2), 
2.98-3.05 (m, 2H, ε-CH2), 3.84 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.89-3.95 (m, 1H, Fmoc-CH), 4.17-4.29 
(m, 3H, α-CH, Fmoc-CH2), 5.31 (s, 2H, DMNB-CH2), 7.14 (s, 1H, DMNB-H6), 7.30 (t, 3JH,H = 7.3 Hz, 2H, 
Fmoc-CH), 7.39 (t, 3JH,H = 7.3 Hz, 2H, Fmoc-CH), 7.53 (d, 3JH,H = 7.9 Hz, 1H, NH), 7.66 (s, 1H, DMNB-H3), 
7.69 (d, 3JH,H = 7.3 Hz, 2H, Fmoc-CH), 7.85 (d, 3JH,H = 7.3 Hz, 2H, Fmoc-CH).   
13C-NMR (126 MHz, [D6]DMSO): δC (ppm) = 23.0 (γ-CH2), 29.0 (δ-CH2), 30.5 (β-CH2), 40.1 (ε-CH2), 46.8 
(Fmoc-CH), 53.9 (α-CH2), 56.2, 56.3 (OCH3), 62.3 (DMNB-CH2), 65.7 (Fmoc-CH2), 108.3 (DMNB-C3), 
110.6 (DMNB-C6), 120.1, 125.3, 127.1, 127.7 (Fmoc-CH), 128.0 (DMNB-C1), 139.4 (DMNB-C2), 140.8, 
143.9 (Fmoc-C), 147.8 (DMNB-C5), 153.4 (DMNB-C4), 155.8, 156.3 (CO), 174.0 (CO2H). 
HR-MS (ESI): calc. for [C31H33N3NaO10]+ ([M+Na]+): 630.2058, found: 630.2039; calc. for [C31H32N3O10]- 








Fmoc-L-Asp-OtBu (39) (912 mg, 2.20 mmol, 1.00 eq.), 4-(dimethylamino)pyridine (156 mg, 1.10 mmol, 
0.50 eq.), 4,5-dimethoxy-2-nitrobenzyl alcohol (562 mg, 2.64 mmol, 1.20 eq.) was dissolved in DCM 
(30 mL) under argon atmosphere and exclusion of light. The reaction mixture was stirred for 10 min at 
0 °C and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (460 mg, 2.40 mmol, 
1.09 eq.) were added. Further stirring for 2 h at 0 °C and overnight at rt was followed by solvent 
removal under reduced pressure. The resulting residue was dissolved in EtOAc (25 mL) and water 
(5 mL). The organic phase was washed with saturated NaHCO3 (aq) (2 x 15 mL), water (2 x 15 mL), dried 
over Na2SO4 and the solvent removed under reduced pressure. The resulting yellow oil was purified by 
flash column chromatography (pentane/EtOAc 2:1, v/v) to yield the product 40 as a yellow solid (1.04 g, 
1.71 mmol, 78%). 
 
TLC (pentane/EtOAc 2:1, v/v): Rf = 0.60. 
1H-NMR (600 MHz, [D6]DMSO): δ (ppm) = 1.36 (s, 9H, C(CH3)3), 2.78-2.82 (m, 2H, β-CH2), 3.85 (s, 3H, 
OCH3), 3.90 (s, 3H, OCH3), 4.20 (t, 3JH,H = 7.0 Hz, 1H, Fmoc-CH), 4.30-4.32 (m, 2H, Fmoc-CH2), 4.37-4.41 
(m, 1H, α-CH), 5.43 (s, 2H, DMNB-CH2), 7.17 (s, 1H, DMNB-H6), 7.29-7.32 (m, 2H, Fmoc-CH), 7.40 (t, 
3JH,H = 7.5 Hz, 2H, Fmoc-CH), 7.67-7.69 (m, 3H, DMNB-H3, Fmoc-CH), 7.75 (d, 3JH,H = 8.4 Hz, 1H, NH), 
7.87 (d, 3JH,H = 7.5 Hz, 2H, Fmoc-CH). 
13C-NMR (126 MHz, [D6]DMSO): δC (ppm) = 27.4 (C(CH3)), 35.9 (β-CH2), 46.6 (Fmoc-CH), 51.0 (α-CH), 
56.0 (OCH3), 56.1 (OCH3), 62.8 (DMNB-CH2), 65.7 (Fmoc-CH2), 81.1 (C(CH3)), 108.1 (DMNB-C3), 111.2 
(DMNB-C6), 120.0, 125.0 (Fmoc-CH), 125.9 (DMNB-C1), 126.9, 127.5 (Fmoc-CH), 139.6 (DMNB-C2), 
140.6, 143.7 (Fmoc-CH), 147.9 (DMNB-C5), 153.2 (DMNB-C4), 155.8 (Fmoc-CO), 169.6, 169.7 (CO). 








According to the procedure of BOURGAULT et al., Fmoc-L-Asp(ODMNB)-OtBu (40) (1.02 g, 1.69 mmol) 
was dissolved in TFA/water (36 mL, 19:1, v/v) and stirred for 90 min.[190] The solvent was removed 
under reduced pressure, the resulting residue was dissolved in DCM (50 mL), washed with 5% KHSO4 
(aq) (3 x 20 mL) and dried over Na2SO4. The solvent was removed under reduced pressure and the 
resulting yellow oil was purified by flash column chromatography (DCM/MeOH/AcOH 9:1:0.1, v/v/v) 
to yield the product 38 as a yellow solid (863 mg, 1.57 mmol, 93%). The NMR data is in accordance to 
the literature.[190] 
 
TLC (DCM/MeOH/AcOH 9:1:0.1, v/v/v): Rf = 0.69. 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 2.77-3.00 (m, 2H, β-CH2), 3.85 (s, 3H, OCH3), 3.90 (s, 3H, 
OCH3), 4.17-4.21 (m, 1H, Fmoc-CH), 4.27-4.30 (m, 2H, Fmoc-CH2), 4.41-4.48 (m, 1H, α-CH), 5.42 (s, 2H, 
DMNB-CH2), 7.16 (s, 1H, DMNB-H6), 7.30 (t, 3JH,H = 7.5 Hz, 2H, Fmoc-CH), 7.40 (t, 3JH,H = 7.5 Hz, 2H, 
Fmoc-CH), 7.66-7.71 (m, 4H, DMNB-H3, Fmoc-CH, NH), 7.87 (d, 3JH,H = 7.5 Hz, 2H, Fmoc-CH). 
13C-NMR (126 MHz, [D6]DMSO): δC (ppm) = 36.0 (β-CH2), 46.6 (Fmoc-CH), 50.5 (α-CH), 56.0 (OCH3), 56.3 
(OCH3), 62.7 (DMNB-CH2), 65.7 (Fmoc-CH2), 108.1 (DMNB-C3), 110.9 (DMNB-C6), 120.0, 125.1 (Fmoc-
CH), 126.3 (DMNB-C1), 127.0, 127.6 (Fmoc-CH), 139.5 (DMNB-C2), 140.7, 143.7 (Fmoc-CH), 147.9 
(DMNB-C5), 153.4 (DMNB-C4), 155.8 (Fmoc-CO), 169.9 (γ-CO), 172.3 (CO2H). 
HR-MS (ESI): calc. for [C28H26N2NaO10]+ ([M+Na]+): 573.1480, found: 573.1471; calc. for [C28H25N2O10]- 






8.4.2 Syntheses of µ-conotoxin SIIIA derivatives 





2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.29 mmol/g. The resin (345 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Ser(2’propyne)-OH following SOP2. The 
peptide was synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm 




HR-MS (ESI): calc. for [C99H156N36O31S7]2+ ([M+2H]2+): 1284.4886, found: 1284.4881; calc. for 













Synthesis of µ-conotoxin SIIIA-[Ser(2’propyne)] (disulphide connectivity: 1-4/2-5/3-6): formation of 




The formation of the first disulphide bridge using the linear precursor 14 (279 mg, 34.2 µmol) was 
performed following SOP7 (24 mL in steps 1-3, 820 mL in step 4, 400 mL in step 5) yielding the product 
18 as a colourless solid (54.2 mg, 21.9 µmol, 64%). 
 
HR-MS (ESI): calc. for [C95H146N36O31S6]2+ ([M+2H]2+): 1239.4634, found: 1239.4627; calc. for 
[C95H147N36O31S6]3+ ([M+3H]3+): 826.6447, found: 826.6437. 
 
Synthesis of µ-conotoxin SIIIA-[Ser(2’propyne)] (disulphide connectivity: 1-4/2-5/3-6): formation of 




The second disulphide bridge using the crude peptide 18 (54.4 mg, 21.9 µmol) was performed following 
SOP8 yielding the product 19 as a colourless solid (49.3 mg, 19.9 µmol, 91%). 
 
HR-MS (ESI): calc. for [C95H144N36O31S6]2+ ([M+2H]2+): 1238.4556, found: 1238.4532; calc. for 










Synthesis of µ-conotoxin SIIIA-[Ser(2’propyne)] (7) (disulphide connectivity: 1-4/2-5/3-6): formation 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
19 (31.8 mg, 12.8 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 9.6 mL), adding Ac-L-Trp-OMe (33.3 mg, 
128 µmol, 10.0 eq.) and a solution of iodine (162 mg, 640 µmol, 50.0 eq.) dissolved in acetic acid 
(6.4 mL) and stirring for 15 min. The reaction was quenched using a solution of L-ascorbic acid in water 
(495 mg in 1.5 mL water) and directly purified by preparative HPLC yielding four differently folded 
peptides 7. 
 
HPLC (preparative, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
0-40% B, 30 min) was utilised for all products. 
 
1. Colourless solid (63.1 µg, 27.1 nmol). 
HPLC: Rt = 22.3 min. 
HR-MS (ESI): calc. for [C89H132N34O29S6]2+ ([M+2H]2+): 1166.4106, found: 1166.4111; calc. for 
[C89H133N34O29S6]3+ ([M+3H]3+): 777.9428, found: 777.9435; calc. for [C89H134N34O29S6]4+ 
([M+4H]4+): 583.7090, found: 583.7091. 
2. Colourless solid (95.0 µg, 40.7 nmol). 
HPLC: Rt = 23.4 min. 
HR-MS (ESI): calc. for [C89H132N34O29S6]2+ ([M+2H]2+): 1166.4106, found: 1166.4094; calc. for 
[C89H133N34O29S6]3+ ([M+3H]3+): 777.9428, found: 777.9431; calc. for [C89H134N34O29S6]4+ 
([M+4H]4+): 583.7090, found: 583.7098. 
3. Colourless solid (143 µg, 61.4 nmol). 
HPLC: Rt = 24.1 min. 
HR-MS (ESI): calc. for [C89H132N34O29S6]2+ ([M+2H]2+): 1166.4106, found: 1166.4113; calc. for 
[C89H133N34O29S6]3+ ([M+3H]3+): 777.9428, found: 777.9438; calc. for [C89H134N34O29S6]4+ 
([M+4H]4+): 583.7090, found: 583.7095. 
4. Colourless solid (106 µg, 45.5 nmol). 




HR-MS (ESI): calc. for [C89H132N34O29S6]2+ ([M+2H]2+): 1166.4106, found: 1166.4113; calc. for 
[C89H133N34O29S6]3+ ([M+3H]3+): 777.9428, found: 777.9441; calc. for [C89H134N34O29S6]4+ 
([M+4H]4+): 583.7090, found: 583.7109. 
 





2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.29 mmol/g. The resin (345 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Cys(Trt)-OH following SOP2. The peptide was 
synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm and StBu 




HR-MS (ESI): calc. for [C94H151N35O29S7]2+ ([M+2H]2+): 1228.9725, found: 1228.9698; calc. for 
[C94H152N35O29S7]3+ ([M+3H]3+): 819.6508, found: 819.6502; calc. for [C94H153N35O29S7]4+ ([M+4H]4+): 










Synthesis of [pGlu1Ser(2’propyne)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The formation of the first disulphide bridge using the linear precursor 65 (279 mg, 34.7 µmol) was 
performed following SOP7 (24 mL in steps 1-3, 820 mL in step 4, 400 mL in step 5) yielding the product 
67 as a colourless solid (38.3 mg, 16.1 µmol, 46%). 
 
HR-MS (ESI): calc. for [C90H141N35O29S6]2+ ([M+2H]2+): 1183.9474, found: 1183.9471; calc. for 
[C90H142N35O29S6]3+ ([M+3H]3+): 789.6340, found: 789.6346. 
 
Synthesis of [pGlu1Ser(2’propyne)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The second disulphide bridge using the crude peptide 67 (38.3 mg, 16.1 µmol) was performed following 
SOP8 yielding the product 68 as a colourless solid (25.5 mg, 10.8 µmol, 67%). 
 
HR-MS (ESI): calc. for [C90H139N35O29S6]2+ ([M+2H]2+): 1182.9396, found: 1182.9393; calc. for 












Synthesis of [pGlu1Ser(2’propyne)]-µ-conotoxin SIIIA (8) (disulphide connectivity: 1-4/2-5/3-6): 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
68 (20.9 mg, 8.83 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 6 mL), adding Ac-L-Trp-OMe (23.0 mg, 
88.3 µmol, 10.0 eq.) and a solution of iodine (112 mg, 442 µmol, 50.0 eq.) dissolved in acetic acid (4 mL) 
and stirring for 15 min. The reaction was quenched using a solution of L-ascorbic acid in water (495 mg 
in 1.5 mL water) and directly purified by preparative HPLC yielding four differently folded peptides 8. 
 
HPLC (preparative, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
0-40% B, 30 min) was utilised for all products. 
 
1. Colourless solid (92.6 µg, 41.7 nmol). 
HPLC: Rt = 22.4 min. 
HR-MS (ESI): calc. for [C84H127N33O27S6]2+ ([M+2H]2+): 1110.8946, found: 1110.8938; calc. for 
[C84H128N33O27S6]3+ ([M+3H]3+): 740.9322, found: 740.9323; calc. for [C84H129N33O27S6]4+ 
([M+4H]4+): 555.9509, found: 555.9498. 
2. Colourless solid (148 µg, 66.7 nmol). 
HPLC: Rt = 23.5 min. 
HR-MS (ESI): calc. for [C84H127N33O27S6]2+ ([M+2H]2+): 1110.8946, found: 1110.8936; calc. for 
[C84H128N33O27S6]3+ ([M+3H]3+): 740.9322, found: 740.9325; calc. for [C84H129N33O27S6]4+ 
([M+4H]4+): 555.9509, found: 555.9508. 
3. Colourless solid (115 µg, 51.7 nmol). 
HPLC: Rt = 24.2 min. 
HR-MS (ESI): calc. for [C84H127N33O27S6]2+ ([M+2H]2+): 1110.8946, found: 1110.8938; calc. for 
[C84H128N33O27S6]3+ ([M+3H]3+): 740.9322, found: 740.9300. 
4. Colourless solid (131 µg, 58.8 nmol). 
HPLC: Rt = 24.7 min. 
HR-MS (ESI): calc. for [C84H127N33O27S6]2+ ([M+2H]2+): 1110.8946, found: 1110.8938; calc. for 
[C84H128N33O27S6]3+ ([M+3H]3+): 740.9322, found: 740.9319; calc. for [C84H129N33O27S6]4+ 









2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.38 mmol/g. The resin (263 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Cys(Trt)-OH following SOP2. The peptide was 
synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm and StBu 




HR-MS (ESI): calc. for [C97H153N35O30S7]2+ ([M+2H]2+): 1255.9778, found: 1255.9778; calc. for 














Synthesis of [Gly6Ser(2’propyne)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The formation of the first disulphide bridge using the linear precursor 69 (213 mg, 30.9 µmol) was 
performed following SOP7 (24 mL in steps 1-3, 820 mL in step 4, 400 mL in step 5) yielding the product 
71 as a colourless solid (56.3 mg, 23.2 µmol, 75%). 
 
HR-MS (ESI): calc. for [C93H143N35O30S6]2+ ([M+2H]2+): 1210.9527, found: 1210.9523; calc. for 
[C93H144N35O30S6]3+ ([M+3H]3+): 807.6375, found: 807.6379. 
 
Synthesis of [Gly6Ser(2’propyne)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The second disulphide bridge using the crude peptide 71 (56.3 mg, 23.2 µmol) was performed following 
SOP8 yielding the product 72 as a colourless solid (55.1 mg, 22.8 µmol, 98%). 
 
HR-MS (ESI): calc. for [C93H141N35O30S6]2+ ([M+2H]2+): 1209.9448, found: 1209.9414; calc. for 










Synthesis of [Gly6Ser(2’propyne)]-µ-conotoxin SIIIA (9) (disulphide connectivity: 1-4/2-5/3-6): 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
72 (21.3 mg, 8.80 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 6 mL), adding Ac-L-Trp-OMe (22.9 mg, 
88.0 µmol, 10.0 eq.) and a solution of iodine (112 mg, 440 µmol, 50.0 eq.) dissolved in acetic acid (4 mL) 
and stirring for 15 min. The reaction was quenched using a solution of L-ascorbic acid in water (495 mg 
in 1.5 mL water) and directly purified by preparative HPLC yielding three differently folded peptides 9. 
 
HPLC (preparative, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
0-40% B, 30 min) was utilised for all products. 
 
1. Colourless solid (219 µg, 96.1 nmol). 
HPLC: Rt = 23.7 min. 
HR-MS (ESI): calc. for [C87H129N33O28S6]2+ ([M+2H]2+): 1137.8999, found: 1137.8996; calc. for 
[C87H130N33O28S6]3+ ([M+3H]3+): 758.9357, found: 758.9366; calc. for [C87H131N33O28S6]4+ 
([M+4H]4+): 569.4536, found: 569.4546. 
2. Colourless solid (204 µg, 89.6 nmol). 
HPLC: Rt = 24.5 min. 
HR-MS (ESI): calc. for [C87H129N33O28S6]2+ ([M+2H]2+): 1137.8999, found: 1137.9006; calc. for 
[C87H130N33O28S6]3+ ([M+3H]3+): 758.9357, found: 758.9371; calc. for [C87H131N33O28S6]4+ 
([M+4H]4+): 569.4536, found: 569.4554. 
3. Colourless solid (484 µg, 213 nmol). 
HPLC: Rt = 26.5 min. 
HR-MS (ESI): calc. for [C87H129N33O28S6]2+ ([M+2H]2+): 1137.8999, found: 1137.9003; calc. for 
[C87H130N33O28S6]3+ ([M+3H]3+): 758.9357, found: 758.9369; calc. for [C87H131N33O28S6]4+ 












Based on the procedure of EMPTING et al., to [Gly6Ser(2’propyne)]-µ-SIIIA (9) (Rt = 24.5 min, 12.5 µg, 
5.50 nmol, 1.00 eq.) and Alexa Fluor® 647 azide triethylammonium salt (4.68 µL, 5.50 nmol, 1.00 eq., 
0.50 mg in 500 µL degassed and argon-flushed water) the catalyst solution (27.5 µL, 1.90 mL degassed 
and argon-flushed water, 0.40 mg copper (II) sulphate pentahydrate (final amount: 189 nmol, 4.00 eq.), 
100 µL 4 mM sodium ascorbate solution (final amount: 5.50 nmol, 1.00 eq.), 0.55 µL DIPEA (final 
amount: 378 nmol, 8.00 eq.)) was added and the reaction mixture shaken at rt for 2 d. The reaction 
mixture was directly purified via analytical HPLC yielding the product 20 as a colourless solid 
(1.00 nmol, 18%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
0-100% B, 30 min): Rt = 14.4 min. 
MS (ESI): calc. for ([M+3H]3+): 1014.4 (based on the Alexa Fluor® 647 azide HR-MS(ESI) ([M-1H]-): 
765.3), found: 1014.4; calc. for ([M+2H+Na]3+): 1021.7, found: 1021.7. 
 





2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.38 mmol/g. The resin (263 mg, 




synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm and StBu 
protected peptide 74. 
 
 
HR-MS (ESI): calc. for [C96H151N35O29S7]2+ ([M+2H]2+): 1240.9725, found: 1240.9721; calc. for 
[C96H152N35O29S7]3+ ([M+3H]3+): 827.6508, found: 827.6512. 
 
Synthesis of [Ser9Ser(2’propyne)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The formation of the first disulphide bridge using the linear precursor 73 (213 mg, 31.3 µmol) was 
performed following SOP7 (24 mL in steps 1-3, 820 mL in step 4, 400 mL in step 5) yielding the product 
75 as a colourless solid (53.6 mg, 22.4 µmol, 72%). 
 
HR-MS (ESI): calc. for [C92H141N35O29S6]2+ ([M+2H]2+): 1195.9474, found: 1195.9463; calc. for 













Synthesis of [Ser9Ser(2’propyne)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The second disulphide bridge using the crude peptide 75 (53.6 mg, 22.4 µmol) was performed following 
SOP8 yielding the product 76 as a colourless solid (52.2 mg, 21.8 µmol, 97%). 
 
HR-MS (ESI): calc. for [C92H139N35O29S6]2+ ([M+2H]2+): 1194.9396, found: 1194.9381; calc. for 
[C92H140N35O29S6]3+ ([M+3H]3+): 796.9621, found: 796.9619. 
 
Synthesis of [Ser9Ser(2’propyne)]-µ-conotoxin SIIIA (10) (disulphide connectivity: 1-4/2-5/3-6): 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
76 (20.3 mg, 8.49 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 6 mL), adding Ac-L-Trp-OMe (22.1 mg, 
84.9 µmol, 10.0 eq.) and a solution of iodine (108 mg, 425 µmol, 50.0 eq.) dissolved in acetic acid (4 mL) 
and stirring for 15 min. The reaction was quenched using a solution of L-ascorbic acid in water (495 mg 
in 1.5 mL water) and directly purified by preparative HPLC yielding three differently folded peptides 
10. 
 
HPLC (preparative, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
0-40% B, 30 min) was utilised for all products. 
 
1. Colourless solid (371 µg, 165 nmol). 




HR-MS (ESI): calc. for [C86H127N33O27S6]2+ ([M+2H]2+): 1122.8946, found: 1122.8946; calc. for 
[C86H128N33O27S6]3+ ([M+3H]3+): 748.9322, found: 748.9334; calc. for [C86H129N33O27S6]4+ 
([M+4H]4+): 561.9509, found: 561.9524. 
2. Colourless solid (497 µg, 221 nmol). 
HPLC: Rt = 24.1 min. 
HR-MS (ESI): calc. for [C86H127N33O27S6]2+ ([M+2H]2+): 1122.8946, found: 1122.8946; calc. for 
[C86H128N33O27S6]3+ ([M+3H]3+): 748.9322, found: 748.9337; calc. for [C86H129N33O27S6]4+ 
([M+4H]4+): 561.9509, found: 561.9526. 
3. Colourless solid (499 µg, 222 nmol). 
HPLC: Rt = 26.2 min. 
HR-MS (ESI): calc. for [C86H127N33O27S6]2+ ([M+2H]2+): 1122.8946, found: 1122.8950; calc. for 
[C86H128N33O27S6]3+ ([M+3H]3+): 748.9322, found: 748.9333; calc. for [C86H129N33O27S6]4+ 
([M+4H]4+): 561.9509, found: 561.9527. 
 




Based on the procedure of EMPTING et al., to [Ser9Ser(2’propyne)]-µ-SIIIA (10) (Rt = 23.9 min, 106 µg, 
47.3 nmol, 1.00 eq.) and Alexa Fluor® 647 azide triethylammonium salt (40.2 µL, 47.3 nmol, 1.00 eq., 
0.50 mg in 500 µL degassed and argon-flushed water) the catalyst solution (237 µL, 1.90 mL degassed 
and argon-flushed water, 0.40 mg copper (II) sulphate pentahydrate (final amount: 189 nmol, 4.00 eq.), 
100 µL 4 mM sodium ascorbate solution (final amount: 47.3 nmol, 1.00 eq.), 0.55 µL DIPEA (final 
amount: 378 nmol, 8.00 eq.)) was added and the reaction mixture shaken at rt for 2 d. The reaction 
mixture was directly purified via analytical HPLC yielding two products 21 with identical mass. 
 
1. Blue solid (1.18 nmol, 3%). 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
10-40% B, 30 min): Rt = 25.2 min. 
MS (MALDI): calc. for ([M+H]+): 3011.1 (based on the Alexa Fluor® 647 azide HR-MS(ESI) 





2. Blue solid (4.03 nmol, 9%). 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
10-40% B, 30 min): Rt = 25.8 min. 
MS (MALDI): calc. for ([M+H]+): 3011.1 (based on the Alexa Fluor® 647 azide HR-MS(ESI) 
([M-1H]-): 765.3), found: 3011.2. 
 





2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.47 mmol/g. The resin (213 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Cys(Trt)-OH following SOP2. The peptide was 
synthesized following SOP4. Product 22 was directly used for the next step. 
 
Synthesis of [Gly6Cys(Mbzl)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): formation of 




The formation of the first disulphide bridge using the linear precursor 22 (172 mg, 26.6 µmol) was 
performed following SOP7 (24 mL in steps 1-3, 820 mL in step 4, 400 mL in step 5) yielding the product 





HR-MS (ESI): calc. for [C98H149N35O29S7]2+ ([M+2H]2+): 1251.9647, found: 1251.9641; calc. for 
[C98H150N35O29S7]3+ ([M+3H]3+): 834.9789, found: 834.9802; calc. for [C98H151N35O29S7]4+ ([M+4H]4+): 
626.4860, found: 626.4871. 
 
Synthesis of [Gly6Cys(Mbzl)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): formation of 




The second disulphide bridge using the crude peptide 23 (67.4 mg, 26.9 µmol) was performed following 
SOP8 yielding the product 24 as a colourless solid (24.1 mg, 9.63 µmol, 36%). 
 
HR-MS (ESI): calc. for [C98H147N35O29S7]2+ ([M+2H]2+): 1250.9569, found: 1250.9569; calc. for 
[C98H148N35O29S7]3+ ([M+3H]3+): 834.3070, found: 834.3081. 
 
Synthesis of [Gly6Cys(Mbzl)]-µ-conotoxin SIIIA (25) (disulphide connectivity: 1-4/2-5/3-6): formation 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
24 (10.0 mg, 4.00 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 3 mL), adding Ac-L-Trp-OMe (10.4 mg, 
40.0 µmol, 10.0 eq.) and a solution of iodine (50 mg, 200 µmol, 50.0 eq.) dissolved in acetic acid (2 mL) 
and stirring for 1 h at rt. The solvent was removed under reduced pressure. The crude peptide was 
dissolved in a small amount of TFA and precipitated with cold diethyl ether, isolated by centrifugation 
(9000 rpm, 2.5 min, -10 °C), washed three times with cold diethyl ether followed by centrifugation and 
dried overnight under reduced pressure to yield the crude product 25 as a colourless solid (2.11 mg, 
0.89 µmol, 22%). 
 
HR-MS (ESI): calc. for [C92H135N33O27S7]2+ ([M+2H]2+): 1178.9120, found: 1178.9124; calc. for 









2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.47 mmol/g. The resin (213 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Cys(Trt)-OH following SOP2. The peptide was 
synthesized following SOP4. Product 77 was directly used for the next step. 
 
Synthesis of C-terminal elongated µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The formation of the first disulphide bridge using the linear precursor 77 (279 mg, 34.7 µmol) was 
performed following SOP7 (24 mL in steps 1-3, 820 mL in step 4, 400 mL in step 5) yielding the product 










Synthesis of C-terminal elongated µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): 




The second disulphide bridge using the crude peptide 78 (101 mg, 37.3 µmol) was performed following 
SOP8 yielding the product 79 as a colourless solid (8.20 mg, 3.47 µmol, 9%). 
 
HR-MS (ESI): calc. for [C106H161N37O33S7]2+ ([M+2H]2+): 1352.0046, found: 1352.0041; calc. for 
[C106H162N37O33S7]3+ ([M+3H]3+): 901.6721, found: 901.6722. 
 
Synthesis of C-terminal elongated µ-conotoxin SIIIA 26 (disulphide connectivity: 1-4/2-5/3-6): 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
79 (8.20 mg, 3.03 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 4.50 mL), adding Ac-L-Trp-OMe (7.80 mg, 
30.3 µmol, 10.0 eq.) and a solution of iodine (38.5 mg, 150 µmol, 50.0 eq.) dissolved in acetic acid 
(3 mL) and stirring for 15 min. The solvent was removed under reduced pressure. The crude peptide 
was dissolved in a small amount of TFA and precipitated with cold diethyl ether, isolated by 
centrifugation (9000 rpm, 2.5 min, -10 °C), washed three times with cold diethyl ether followed by 
centrifugation and dried overnight under reduced pressure. The crude peptide 26 was purified by 





HPLC (preparative, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
5-50% B, 30 min): Rt = 26.8 min. 
HR-MS (ESI): calc. for [C100H149N35O31S7]2+ ([M+2H]2+): 1279.9596, found: 1279.9580; calc. for 
[C100H150N35O31S7]3+ ([M+3H]3+): 853.6422, found: 853.6428. 
 




2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.36 mmol/g. The resin (278 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Cys(Trt)-OH following SOP2. The peptide was 
synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm and StBu 




HR-MS (ESI): calc. for [C93H149N35O29S7]2+ ([M+2H]2+): 1221.9647, found: 1221.9652; calc. for 
[C93H150N35O29S7]3+ ([M+3H]3+): 814.9789, found: 814.9795; calc. for [C93H151N35O29S7]4+ ([M+4H]4+): 











Synthesis of µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): formation of the first 




The formation of the first disulphide bridge using the linear precursor 80 (495 mg, 28.9 µmol) was 
performed following SOP7 (6 mL in steps 1-3, 205 mL in step 4, 100 mL in step 5) yielding the product 
82 as a colourless solid (55.1 mg, 23.4 µmol, 81%). 
 
HR-MS (ESI): calc. for [C89H139N35O29S6]2+ ([M+2H]2+): 1176.9396, found: 1176.9403; calc. for 
[C89H140N35O29S6]3+ ([M+3H]3+): 784.9621, found: 784.9614. 
 
Synthesis of µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): formation of the second 




The second disulphide bridge using the crude peptide 82 (55.1 mg, 23.4 µmol) was performed following 
SOP8 yielding the product 83 as a colourless solid (40.4 mg, 17.2 µmol, 73%). 
 
HR-MS (ESI): calc. for [C89H137N35O29S6]2+ ([M+2H]2+): 1175.9317, found: 1175.9323; calc. for 
[C89H138N35O29S6]3+ ([M+3H]3+): 784.2902, found: 784.2913; calc. for [C89H139N35O29S6]4+ ([M+4H]4+): 















Synthesis of µ-conotoxin SIIIA 3 (disulphide connectivity: 1-4/2-5/3-6): formation of the third 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
83 (11.4 mg, 4.85 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 3.60 mL), adding Ac-L-Trp-OMe (12.5 mg, 
48.5 µmol, 10.0 eq.) and a solution of iodine (60.9 mg, 240 µmol, 50.0 eq.) dissolved in acetic acid 
(2.40 mL) and stirring for 15 min. The reaction was quenched using a solution of L-ascorbic acid in water 
(495 mg in 1.5 mL water) and directly purified by preparative HPLC. The peak having the same retention 
time as commercially available µ-SIIIA was collected yielding the product 3 as a colourless solid 
(0.25 mg, 115 nmol, 2%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 0-40% B, 
30 min): Rt = 18.2 min. 
HR-MS (ESI): calc. for [C83H125N33O27S6]2+ ([M+2H]2+): 1103.8868, found: 1103.8872; calc. for 
[C83H126N33O27S6]3+ ([M+3H]3+): 736.2603, found: 736.2612; calc. for [C83H127N33O27S6]4+ ([M+4H]4+): 
552.4474, found: 552.4470. 
 




2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.36 mmol/g. The resin (278 mg, 
0.10 mmol) was loaded with the first amino acid Fmoc-L-Cys(Trt)-OH following SOP2. The peptide was 
synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm and StBu 






HR-MS (ESI): calc. for [C93H149N35O29S7]2+ ([M+2H]2+): 1221.9647, found: 1221.9621; calc. for 
[C93H150N35O29S7]3+ ([M+3H]3+): 814.9789, found: 814.9779. 
 
Synthesis of µ-conotoxin SIIIA (disulphide connectivity: 1-5/2-4/3-6): formation of the first 




The formation of the first disulphide bridge using the linear precursor 84 (515 mg, 31.6 µmol) was 
performed following SOP7 (6 mL in steps 1-3, 205 mL in step 4, 100 mL in step 5) yielding the product 
86 as a colourless solid (53.0 mg, 22.5 µmol, 71%). 
 
HR-MS (ESI): calc. for [C89H139N35O29S6]2+ ([M+2H]2+): 1176.9396, found: 1176.9397; calc. for 
[C89H140N35O29S6]3+ ([M+3H]3+): 784.9621, found: 784.9614. 
 
Synthesis of µ-conotoxin SIIIA (disulphide connectivity: 1-5/2-4/3-6): formation of the second 




The second disulphide bridge using the crude peptide 86 (53.0 mg, 22.5 µmol) was performed following 
SOP8 yielding the product 87 as a colourless solid (39.8 mg, 16.9 µmol, 75%). 
 
HR-MS (ESI): calc. for [C89H137N35O29S6]2+ ([M+2H]2+): 1175.9317, found: 1175.9319; calc. for 
[C89H138N35O29S6]3+ ([M+3H]3+): 784.2902, found: 784.2909; calc. for [C89H139N35O29S6]4+ ([M+4H]4+): 




Synthesis of µ-conotoxin SIIIA 27 (disulphide connectivity: 1-5/2-4/3-6): formation of the third 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the crude peptide 
87 (11.8 mg, 5.02 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 3.60 mL), adding Ac-L-Trp-OMe (13.1 mg, 
50.2 µmol, 10.0 eq.) and a solution of iodine (63.7 mg, 251 µmol, 50.0 eq.) dissolved in acetic acid 
(2.40 mL) and stirring for 15 min. The reaction was quenched using a solution of L-ascorbic acid in water 
(495 mg in 1.5 mL water) and directly purified by preparative HPLC. The peak having the same retention 
time as commercially available µ-SIIIA was collected yielding the product 27 as a colourless solid 
(0.52 mg, 234 nmol, 5%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 0-40% B, 
30 min): Rt = 18.2 min. 
HR-MS (ESI): calc. for [C83H125N33O27S6]2+ ([M+2H]2+): 1103.8868, found: 1103.8876; calc. for 
[C83H126N33O27S6]3+ ([M+3H]3+): 736.2603, found: 736.2619; calc. for [C83H127N33O27S6]4+ ([M+4H]4+): 
552.4474, found: 552.4479. 
 





2-Chlorotrityl chloride resin (0.70 g, 0.70 mmol, 1-1.50 mmol/g) was preloaded following SOP1. The 
occupancy was tested following SOP3 and determined to be 0.39 mmol/g. The resin (256 mg, 




synthesized following SOP4. Test cleavage was performed using SOP6/A yielding the Acm and StBu 




HR-MS (ESI): calc. for [C103H158N36O35S7]2+ ([M+2H]2+): 1341.4862, found: 1341.4878; calc. for 
[C103H159N36O35S7]3+ ([M+3H]3+): 894.6599, found: 894.6607. 
 
Synthesis of [Lys11Lys(NVOC)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): formation of 




The formation of the first disulphide bridge using the linear precursor 41 (225 mg, 30.8 µmol) was 
performed following SOP7 (18 mL in steps 1-3, 309 mL in step 4, 148 mL in step 5) yielding the product 
42 as a colourless solid (51.0 mg, 19.7 µmol, 64%). 
 
HR-MS (ESI): calc. for [C99H148N36O35S6]2+ ([M+2H]2+): 1296.4611, found: 1296.4596; calc. for 
[C99H149N36O35S6]3+ ([M+3H]3+): 864.6431, found: 864.6418. 
 
Synthesis of [Lys11Lys(NVOC)]-µ-conotoxin SIIIA (disulphide connectivity: 1-4/2-5/3-6): formation of 




The second disulphide bridge using the crude peptide 42 (51.0 mg, 19.7 µmol) was performed following 





HR-MS (ESI): calc. for [C99H146N36O35S6]2+ ([M+2H]2+): 1295.4532, found: 1295.4540; calc. for 
[C99H147N36O35S6]3+ ([M+3H]3+): 863.9712, found: 863.9717. 
 
A small amount of crude peptide was purified by preparative HPLC to yield a colourless solid (2.4 mg, 
0.92 µmol). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
10-60% B, 30 min): Rt = 19.4 min. 
HR-MS (ESI): calc. for [C99H146N36O35S6]2+ ([M+2H]2+): 1295.4532, found: 1295.4541; calc. for 
[C99H147N36O35S6]3+ ([M+3H]3+): 863.9712, found: 863.9713. 
 
Synthesis of [Lys11Lys(NVOC)]-µ-conotoxin SIIIA (44) (disulphide connectivity: 1-4/2-5/3-6): 




The Acm-groups were removed and the last disulphide bridge formed by dissolving the purified 
peptide 43 (2.40 mg, 0.93 µmol, 1.00 eq.) in AcOH/water (2:1, v/v, 696 µL), adding Ac-L-Trp-OMe 
(2.41 mg, 9.26 µmol, 10.0 eq.) and a solution of iodine (11.8 mg, 46.3 µmol, 50.0 eq.) dissolved in acetic 
acid (464 µL) and stirring for 2 h. The solvent was removed under reduced pressure and co-evaporated 
three times with toluene. The resulting residue was dissolved in a small amount of TFA and precipitated 
with cold diethyl ether, isolated by centrifugation (9000 rpm, 2.5 min, -10 °C), washed three times with 
cold diethyl ether followed by centrifugation and dried overnight under reduced pressure. The crude 
product was purified by preparative HPLC to yield the product 44 as a colourless solid (187 µg, 
75.5 nmol, 8%). 
 
HPLC (preparative, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
10-60% B, 30 min): Rt = 23.8 min. 
HR-MS (ESI): calc. for [C93H134N34O33S6]2+ ([M+2H]2+): 1223.4083, found: 1223.4108; calc. for 
[C93H135N34O33S6]3+ ([M+3H]3+): 815.9413, found: 815.9428; calc. for [C93H134N34NaO33S6]3+ 










[Ser11Ser(2’-propyne)]-β-pompilidotoxin (45) was synthesized on rink amide MBHA resin (loading 
0.57 mmol/g). Therefore, the resin was preloaded following SOP2 using Fmoc-L-Leu-OH as the first 
amino acid followed by capping with 10% acetic anhydride in NMP (3 x 6 mL). The occupancy was 
determined by SOP3 (0.31 mmol/g). The peptide was synthesized with automated SPPS following 
SOP4. Cleavage was performed following SOP6/B. The crude product was dissolved in water and 
purified by preparative HPLC to yield the product 45 as a colourless solid (22.4 mg, 14.0 µmol, 14%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
30-50% B, 30 min): Rt = 18.9 min. 
HR-MS (ESI): calc. for [C74H127N22O17]+ ([M+H]+): 1595.9744, found: 1595.9752; calc. for 
[C74H128N22O17]2+ ([M+2H]2+): 798.4908, found: 798.4909; calc. for [C74H129N22O17]3+ ([M+3H]3+): 






[Ser11Cys]-β-pompilidotoxin (46) was synthesized on rink amide MBHA resin (loading 0.57 mmol/g). 
Therefore, the resin was preloaded following SOP2 using Fmoc-L-Leu-OH as the first amino acid 
followed by capping with 10% acetic anhydride in NMP (3 x 6 mL). The occupancy was determined by 
SOP3 (0.31 mmol/g). The peptide was synthesized with automated SPPS following SOP4. Cleavage was 
performed following SOP6/B. The crude product was dissolved in water and purified by preparative 





HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
30-50% B, 30 min): Rt = 19.5 min. 
HR-MS (ESI): calc. for [C71H125N22O16S]+ ([M+H]+): 1573.9359, found: 1573.9354; calc. for 
[C71H126N22O16S]2+ ([M+2H]2+): 787.4716, found: 787.4724; calc. for [C71H127N22O16S]3+ ([M+3H]3+): 
525.3168, found: 525.3167. 
 




Based on the procedure of LUMIPROBE, [Ser11Cys]-β-pompilidotoxin (46) (1.97 mg, 1.25 µmol, 0.90 eq.) 
was dissolved in 50 mM degassed phosphate buffer (2.78 mL, pH = 7.08) under argon atmosphere.[238] 
TCEP solution (77 µL, 10.0 µmol, 8.00 eq., 0.13 M solution in 50 mM degassed phosphate buffer) was 
added and the solution stirred for 5 min. Under exclusion of light Alexa Fluor® 488 C5 maleimide 
(139 µL, 1.39 µmol, 1.00 eq., 10 mM solution in DMF) was added and the reaction mixture stirred for 
2 h at rt and stored overnight at 4 °C. The solution was diluted 1:1 with acetonitrile and purified by 
preparative HPLC to yield the product 49 as an orange solid (0.97 mg, 426 nmol, 34%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
25-55% B, 30 min): Rt = 22.6 min. 
HR-MS (ESI): calc. for [C101H152N26O28S3]2+ ([M+2H]2+): 1136.5210, found: 1136.5172; calc. for 














[Ser(2’-propyne)]-β-pompilidotoxin (47) was synthesized on rink amide MBHA resin (loading 
0.57 mmol/g). Therefore, the resin was preloaded following SOP2 using Fmoc-L-Leu-OH as the first 
amino acid followed by capping with 10% acetic anhydride in NMP (3 x 6 mL). The occupancy was 
determined by SOP3 (0.31 mmol/g). The peptide was synthesized with automated SPPS following 
SOP4. Cleavage was performed following SOP6/B. The crude product was dissolved in water and 
purified by preparative HPLC to yield the product 47 as a colourless solid (15.1 mg, 8.97 µmol, 9%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
30-50% B, 30 min): Rt = 17.8 min. 
HR-MS (ESI): calc. for [C77H132N23O19]+ ([M+H]+): 1683.0064, found: 1683.0060; calc. for 
[C77H133N23O19]2+ ([M+2H]2+): 842.0069, found: 842.0069; calc. for [C77H134N23O19]3+ ([M+3H]3+): 






[Cys]-β-pompilidotoxin (48) was synthesized on rink amide MBHA resin (loading 0.29 mmol/g). 
Therefore, the resin was preloaded following SOP2 using Fmoc-L-Leu-OH as the first amino acid. The 
peptide was synthesized with manual SPPS following SOP5. Cleavage was performed following SOP6/A 
for 3 h. The crude product was dissolved in water and purified by preparative HPLC to yield the product 
48 as a colourless solid (45.3 mg, 27.3 µmol, 27%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 




HR-MS (ESI): calc. for [C74H130N23O18S]+ ([M+H]+): 1660.9679, found: 1660.9654; calc. for 
[C74H131N23O18S]2+ ([M+2H]2+): 830.9876, found: 830.9832; calc. for [C74H132N23O18S]3+ ([M+3H]3+): 
554.3275, found: 554.3268. 
 




Based on the procedure of LUMIPROBE, [Cys]-β-pompilidotoxin (48) (0.66 mg, 0.40 µmol, 0.80 eq.) was 
dissolved in 50 mM degassed phosphate buffer (1 mL, pH = 7.08) under argon atmosphere.[238] TCEP 
solution (40 µL, 8.00 µmol, 16.0 eq., 0.20 M solution in 50 mM degassed phosphate buffer) were added 
and the solution stirred for 5 min. Under exclusion of light Alexa Fluor® 488 C5 maleimide (50 µL, 
0.50 µmol, 1.00 eq., 10 mM solution in DMF) was added and the reaction mixture stirred for 2 h at rt 
and stored overnight at 4 °C. The solution was diluted 1:1 with acetonitrile and purified by preparative 
HPLC to yield the product 50 as an orange solid (0.09 µg, 39.0 nmol, 10%). 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
20-50% B, 30 min): Rt = 26.5 min. 
HR-MS (ESI): calc. for [C104H157N27O30S3]2+ ([M+2H]2+): 1180.0370, found: 1180.0364; calc. for 
[C104H155N27Na2O30S3]2+ ([M+2Na]2+): 1202.0190, found: 1202.0190; calc. for [C104H158N27O30S3]3+ 















Based on the procedure in the molecular probes® handbook, iberiotoxin (51) (RTI400 ALOMONE LABS, 
0.10 mg, 23.5 nmol, 1.00 eq.) was centrifuged at 10000 x g for 2 min and under an argon blanket DMF 
(34.0 µL), triethylamine (0.69 µL, 100 mM, 3.00 eq.) and a solution of Alexa Fluor® 546 carboxylic acid, 
succinimidyl ester (reactive towards amines) (0.02 mg, 16.1 nmol, 0.70 eq. in 16 µL DMF) were 
added.[233] The solution was stirred overnight at rt and evaporated under reduced pressure. The 
resulting residue was dissolved in an appropriate amount of MeCN/H2O (1:4, v/v) and purified by HPLC 
yielding the product 52 as a pink solid. 
 
HPLC (analytical, A (99.9% H2O, 0.10% TFA), B (79.9% MeCN, 20.0% H2O, 0.10% TFA), gradient 
25-50% B, 30 min): Rt = 24.5 min. 
HR-MS (ESI): calc. for [C219H321Cl3N53O67S10]3+ ([M+3H]3+): 1729.9866, found: 1729.9980; calc. for 
[C219H322Cl3N53O67S10]4+ ([M+4H]4+): 1297.7417, found: 1297.7464; calc. for [C219H323Cl3N53O67S10]5+ 











According to the procedure of KOCSIS et al., pyridinium chlorochromate (9.28 g, 43.0 mmol, 2.00 eq.) 
was dissolved in DCM (85 mL) under an argon atmosphere.[226] 5-Hexynol (54) (2.4 mL, 2.11 g, 
21.5 mmol, 1.00 eq.) was added and the mixture stirred for 2 h. Diethyl ether (70 mL) and silica (25.9 g) 
were added and the mixture stirred for 30 min. After filtration over silica and washing with diethyl 
ether, the solution was evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (pentane/diethyl ether 10:1, v/v) to yield the product 55 as a slightly yellow 
solid (528 mg, 5.49 mmol, 26%). The NMR data is in accordance to the literature.[239]  
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.76-1.85 (m, 2 H, CH2CH2CHO), 1.95 (t, 4JH,H = 2.6 Hz, 1H, CCH), 
2.23 (td, 3,4JH,H = 6.0, 2.7 Hz, 2H, CH2CCH), 2.57 (td, 3,3JH,H = 7.2, 1.3 Hz, 2H, CH2CHO), 9.76 (t, 3JH,H = 1.3 Hz, 
1H, CHO). 
 




Based on the procedure of KATAOKA et al., adenosine-3’,5’-cyclic monophosphate (53) (0.50 g, 
1.52 mmol, 1.00 eq.) was dissolved in water (2.5 mL) and ethanol (2.5 mL), tri-n-butylamine (356 µL, 
1.52 mmol, 1.00 eq.) was added and the mixture stirred until the residue was dissolved (1 h).[225] The 
solvent was evaporated under reduced pressure, co-evaporated with dioxane and the residue dried 
under reduced pressure. Adenosine-3’,5’-cyclic monophosphate tri-n-butylammonium salt (56) 




(528 mg, 5.49 mmol, 5.65 eq.) was added. After 30 min sodium cyanoborohydride (305 mg, 4.86 mmol, 
5.00 eq.) was added and the reaction mixture stirred overnight at 50 °C. The reaction was quenched 
with water and the solvent was evaporated under reduced pressure. HPLC purification yielded the pure 
product 57 as a colourless solid (34.8 mg, 68.2 µmol, 7%). 
 
HPLC (semipreparative, A (0.10 M TEAA buffer pH 7), B (70% MeCN, 30% 0.10 M TEAA pH 7), gradient 
5-60% B, 25 min): Rt = 19.3 min. 
1H-NMR (300 MHz, D2O, 35 °C): δ (ppm) = 1.31 (t, 3JH,H = 7.3 Hz, 9H, CH3), 1.53-1.65 (m, 2H, 
CH2CH2CCH), 1.69-1.78 (m, 2H, NHCH2CH2), 2.23 (td, 3,4JH,H = 6.9, 2.6 Hz, 2H, CH2CCH), 2.37 (t, 
4JH,H = 2.6 Hz, 1H, CCH), 3.23 (q, 3JH,H = 7.3 Hz, 6H, CH2CH3), 3.49 (t, 3JH,H = 6.8 Hz, 2H, NHCH2), 4.41-4.84 
(m, 5H, H2’, H3’, H4’, H5’), 6.10 (s, 1H, H1’), 8.14 (s, 1H, H8), 8.16 (s, 1H, H2). 
13C-NMR (126 MHz, D2O, 35 °C): δC (ppm) = 5.6 (CH3), 14.7 (CH2CCH), 22.4 (CH2CH2CCH), 25.0 
(NHCH2CH2), 37.6 (NHCH2), 44.0 (CH2CH3), 64.5 (d, 2JC,P = 6.9 Hz, C5’), 65.3 (CCH), 69.0 (d, 2JC,P = 4.3 Hz, 
C3’), 69.6 (d, 3JC,P = 7.9 Hz, C2’), 74.5 (d, 3JC,P = 4.5 Hz, C4’), 83.0 (CH2CCH), 88.6 (C1’), 115.9 (C5), 136.0 
(C8), 144.2 (C4), 150.0 (C2), 151.4 (C6). 
31P-NMR (122 MHz, D2O, 35 °C): δP (ppm) = -2.85. 
HR-MS (ESI): calc. for [C16H21N5O6P]+ ([M+H]+): 410.1224, found: 410.1226; calc. for [C16H20N5NaO6P]+ 




















Alexa Fluor® 488 labelled N6-hex-5-yn-1-yladenosine-3’,5’-cyclic monophosphate tri-n-




Based on the procedure of SEELA et al. and the manual for Alexa Fluor® 488 azide, Alexa Fluor® 488 
5-carboxamido-(6-azidohexanyl), bis(triethylammonium salt) (0.50 mg, 581 nmol, 1.06 eq.) was 
dissolved in DMF (9 µL) and combined with N6-hex-5-yn-1-yladenosine-3’,5’-cyclic monophosphate tri-
n-ethylammonium salt (57) (0.28 mg, 548 nmol, 1.00 eq.) dissolved in DMF (8 µL).[227] Sodium ascorbate 
(1.74 µL, 0.1 M solution in water, 174 nmol, 0.32 eq.) and copper (II) sulphate pentahydrate (1.03 µL, 
0.05 M solution in DMF, 51.3 nmol, 0.09 eq.) were added, the solution was centrifuged shortly and 
stirred for 16 h at rt. The solvent was evaporated under reduced pressure, the residue dissolved in 
0.1 M TEAA buffer and purified by HPLC to yield the product 58 as an orange solid (0.08 mg, 65.8 nmol, 
12%). 
  
HPLC (analytical, A (0.10 M TEAA buffer pH 7), B (70% MeCN, 30% 0.10 M TEAA buffer pH 7), gradient 
0-40% B, 30 min): Rt = 23.4 min. 
HR-MS (ESI): calc. for [C43H45N11O16PS2]- ([M-H]-): 1066.2230, found: 1066.2247; calc. for 
[C43H44N11NaO16PS2]- ([M-2H+Na]-): 1088.2050, found: 1088.2049; calc. for 















According to the procedure of SHARMA et al., phosphorus tribromide (1.71 mL, 18.2 mmol, 2.80 eq.) 
was added dropwise to 5-hexynol (54) (5.62 mL, 50.9 mmol, 1.00 eq.) in anhydrous diethyl ether 
(18 mL) at -5 °C.[229] The reaction was stirred for 2 h at -5 °C, warmed to rt and quenched with cold 
saturated NaHCO3 (aq) (10 mL). The organic phase was washed with saturated NaHCO3 (aq) (10 mL) 
and the combined aqueous phases were extracted with diethyl ether (10 mL). The solvent was 
removed under reduced pressure and the crude product distillated (70 °C, 23 mbar) to yield the 
product 89 as a colourless liquid (1.89 g, 11.7 mmol, 23%). 
 
1H-NMR (600 MHz, CDCl3): δ (ppm) = 1.61-1.70 (m, 2H, Br (CH2)2CH2), 1.96-2.00 (m, 3H, CH, BrCH2CH2), 
2.23 (td, 3,4JH,H = 7.0, 2.7 Hz, 2H, CH2CCH), 3.43 (t, 2H, 3JH,H = 6.7 Hz, BrCH2). 
13C-NMR (126 MHz, CDCl3): δC (ppm) = 17.7 (CH2CCH), 26.9 (Br(CH2)2CH2), 31.7 (BrCH2CH2), 33.2 (BrCH2), 
69.0 (CH), 83.7 (CCH). 
 




Based on the procedure of KATAOKA et al., adenosine-3’,5’-cyclic monophosphate (53) (110 mg, 
333 µmol, 1.00 eq.) was added to a stirred solution of KOH (149 mg, 2.66 mmol, 8.00 eq.) in water 
(3 mL).[228] A solution of 18-crown-6 (264 mg, 999 µmol, 3.00 eq.) in dioxane (3 mL) was added, followed 
by 1-bromo-5-hexyne (89) (322 mg, 2.00 mmol, 6.00 eq.). The mixture was stirred at 50-60 °C for 2 d. 




and the solvent removed under reduced pressure. HPLC purification yielded the pure product 62 as a 
colourless solid (94.2 mg, 185 µmol, 55%). 
 
HPLC (analytical, 0.95 mL/min, A (0.10 M TEAA buffer pH 7), B (70% MeCN, 30% 0.10 M TEAA buffer 
pH 7), gradient 5-50% B, 25 min): Rt = 18.8 min. 
1H-NMR (300 MHz, [D6]DMSO, 35 °C): δ (ppm) = 1.09 (t, 3JH,H = 7.2 Hz, 9H, CH3), 1.47-1.68 (m, 4H, 
OCH2CH2CH2), 2.18 (td, 3,4JH,H = 6.9, 2.6 Hz, 2H, CH2CCH), 2.69 (d, 4JH,H = 2.6 Hz, 1H, CCH), 2.80 (q, 
3JH,H = 7.2 Hz, 6H, CH2CH3), 3.51-3.72 (m, 2H, OCH2), 3.87-4.19 (m, 3H, H3’, H5’), 4.41 (d, 3JH,H = 5.2 Hz, 
1H, H2’), 4.77-4.83 (m, 1H, H4’), 6.02 (s, 1H, H1’), 7.28 (s, 2H, NH2), 8.16 (s, 1H, H2), 8.27 (s, 1H, H8). 
13C-NMR (126 MHz, [D6]DMSO, 35 °C): δC (ppm) = 9.8 (CH3), 17.4 (CH2CCH), 24.6 (CH2CH2CCH), 28.3 
(OCH2CH2), 45.5 (CH2CH3), 65.6 (d, 2JC,P = 6.6 Hz, C5’), 69.4 (OCH2), 71.1 (CCH), 72.4 (d, 2JC,P = 3.4 Hz, 
C3’), 77.0 (d, 3JC,P = 4.5 Hz, C4’), 79.2 (d, 3JC,P = 7.4 Hz, C2’), 84.3 (CH2CCCH), 89.6 (C1’), 119.1 (C5), 139.6 
(C8), 148.7 (C4), 152.8 (C2), 156.0 (C6). 
31P-NMR (122 MHz, [D6]DMSO, 35 °C): δP (ppm) = -4.02. 
HR-MS (ESI): calc. for [C16H19N5O6P]- ([M-H]-): 408.1078, found: 408.1071. 
 
Alexa Fluor® 555 labelled 2’O-hex-5-yn-1-yladenosine-3’,5’-cyclic monophosphate tri-n-




Based on the procedure of SEELA et al. and the manual for Alexa Fluor® 555 azide, Alexa Fluor® 555 
azide triethylammonium salt (0.50 mg, 588 nmol, 1.00 eq.) was dissolved in DMF (9 µL) and combined 
with 2’O-hex-5-yn-1-yladenosine-3’,5’-cyclic monophosphate tri-n-ethylammonium salt (62) (0.36 mg, 
706 nmol, 1.20 eq.) dissolved in DMF (8 µL).[227] Sodium ascorbate (1.76 µL, 0.10 M solution in water, 
174 nmol, 0.30 eq.) and copper (II) sulphate pentahydrate (1.04 µL, 0.05 M solution in DMF, 51.3 nmol, 
0.09 eq.) were added, the solution was centrifuged shortly and stirred for 16 h at rt. The solvent was 
evaporated under reduced pressure, the residue dissolved in 0.10 M TEAA buffer and purified by HPLC 




HPLC (analytical, 0.95 mL/min, A (0.10 M triethylammonium acetate buffer pH 7), B (70% MeCN, 30% 
0.10 M triethylammonium acetate buffer pH 7), gradient 5-50% B, 25 min): Rt = 21.8 min. 
HR-MS (ESI): calc. for ([M-2H]2-): 573.6999 (based on the Alexa Fluor® 555 azide MS(ESI) ([M-1H]-): 













AcOH Acetic acid 
ATP Adenosine triphosphate 
BK channel Big potassium channel 
Boc Tert-butyloxycarbonyl 
BSA Bovine serum albumin 
Bzl Benzyl 
cAMP Cyclic adenosine-3’,5’-monophosphate 
cAR cAMP receptor 
CD Circular dichroism 
Chtx Charibdotoxin 
CI Chemotactic index 
CID Collision-induced dissociation 


















EDTA Ethylenediaminetetraacetic acid 
ESI Electrospray-ionisation 
EtOAc Ethyl acetate 
EtOH Ethanol 
FDA Food and Drug Administration (US) 
FlAsH-EDT2 4’,5’-Bis(1,3,2-dithioarcolan-2-yl)fluorescein 
Fmoc Fluorenylmethyloxycarbonyl 
GFP Green fluorescent protein 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
HF Hydrofluoric acid 
HOBt 1-Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
HR-MS High resolution mass spectrometry 
Ibtx Iberiotoxin 
LC-MS Liquid chromatography mass spectrometry 
LplA Lipoic acid ligase 
LAP LplA acceptor peptide 




MS Mass spectrometry 
NB 2-nitrobenzyl (a PPG) 
NHS-ester N-Hydroxysuccinimide ester 
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
NTA Nitrilotriacetic acid 
NVOC 6-nitroveratryloxycarbonyl 
ORN Olfactory receptor neuron 
Pbf 2,2,4,6,7-Pentamethyldihydrofurane-5-sulphonyl 
PCC Pyridinium chlorochromate 
PDI Protein-disulphide-isomerase 
PEG Polyethylene glycol 







PNPCl 4-Nitrophenyl chloroformate 
POI Protein of interest 
PPG Photoremovable protecting group 
PTM Post-translational modification 
RP-HPLC Reverse phase HPLC 
RuAAC Ruthenium(II)-catalysed alkyne-azide cycloaddition 
SOP Standard operating procedure 
SPAAC Strain-promoted azide-alkyne cycloaddition 







TEAA Triethylammonium acetate 
TES Triethylsilane 
TFA Trifluoroacetic acid 
TFE 2,2,2-Trifluoroethanol 
TIS Triisopropylsilane 
TLC Thin layer chromatography 
TM Target molecule 
Trt Trityl 
TTX Tetrodotoxin 
VGCC Voltage-gated calcium channel 
VGSC Voltage-gated sodium channel 
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